import { DiseaseDatabase } from '../types';

const window: any = {
  diseaseMetadata: {
    intraabdominal: { icon: '🩺', color: '#16a34a' }
  },
  diseases: {}
};

window._abdomen_en = window._abdomen_en || {
  gastrointestinal: {
    name: 'Gastrointestinal Infections',
    icon: '🦠',
    color: '#ca8a04',
    tables: [
      {
        title: 'Differential Diagnosis of Gastrointestinal Infections',
        headers: ['Disease', 'Pathogen', 'Affected Segment', 'Mechanism', 'Stool Volume', 'Stool Characteristics', 'Fever', 'Key Features / Complications'],
        rows: [
          ['C. difficile', 'C. difficile', 'Large intestine', 'Toxin A/B (inflammation)', 'Moderate/Large', 'Watery, greenish, foul', '+', 'AB-associated, pseudomembrane, toxic megacolon'],
          ['Salmonella', 'Salmonella', 'Small & Large intestine', 'Invasion + Enterotoxin', 'Moderate', 'Watery (rarely bloody)', '++', 'Food poisoning, reptile contact, extraintestinal complications'],
          ['Shigella', 'Shigella', 'Large intestine', 'Invasion + Shiga toxin', 'Small', 'Bloody-mucoid (dysentery)', '++', 'Tenesmus, low infectious dose, HUS'],
          ['Campylobacter', 'Campylobacter', 'Small & Large intestine', 'Invasion + Toxin', 'Moderate', 'Watery/Bloody', '+', 'Pseudoappendicitis, GBS, poultry'],
          ['E. coli (EHEC)', 'E. coli (STEC)', 'Large intestine', 'Shiga toxin', 'Moderate', 'Bloody', '-', 'Afebrile, HUS, beef'],
          ['E. coli (ETEC)', 'E. coli (ETEC)', 'Small intestine', 'Enterotoxin (secretory)', 'Large', 'Watery', '-', 'Traveler\'s diarrhea'],
          ['E. coli (EPEC)', 'E. coli (EPEC)', 'Small intestine', 'Malabsorption', 'Large', 'Watery/Mucoid', '+/-', 'Infantile diarrhea'],
          ['E. coli (EIEC)', 'E. coli (EIEC)', 'Large intestine', 'Invasion', 'Small', 'Bloody-mucoid', '++', 'Dysentery-like, fever'],
          ['Yersinia', 'Yersinia', 'Small & Large intestine', 'Invasion', 'Moderate', 'Watery/Bloody', '+', 'Pseudoappendicitis, reactive arthritis, pork'],
          ['Giardia', 'Giardia', 'Small intestine', 'Malabsorption', 'Large/Moderate', 'Greasy, foul-smelling', '-', 'Bloating, malabsorption, chronic'],
          ['Amoeba', 'E. histolytica', 'Large intestine', 'Invasion/Cytotoxin', 'Small', 'Bloody-mucoid', '+/-', 'Liver abscess, travel'],
          ['Cryptosporidium', 'Cryptosporidium', 'Small intestine', 'Secretory/Malabsorption', 'Large', 'Watery', '-', 'Persistent in immunosuppressed, swimming pools'],
          ['Viral GE', 'Rota/Noro', 'Small intestine', 'Malabsorption/Osmotic', 'Large', 'Watery', '-/+', 'Vomiting dominates (Noro), winter season'],
          ['Cholera', 'Vibrio cholerae', 'Small intestine', 'Enterotoxin (secretory)', 'Very large', 'Rice-water', '-', 'Massive fluid loss, dehydration']
        ]
      }
    ],
    diseases: [
      {
        id: 'cdiff',
        name: 'Clostridioides difficile Infection',
        pathogen: { type: 'Bacterium', name: '<i>Clostridioides difficile</i>', gram: 'Gram-positive', shape: 'spore-forming anaerobic rod' },
        epidemiology: {
          incidence: 'Most common cause of healthcare-associated infectious diarrhea; community-acquired CDI is also increasing. Recurrence follows about 20-30% of successfully treated first episodes.',
          risk_groups: ['Age >65 years', 'Hospitalization, long-term care or recent healthcare exposure', 'Antibiotics in the previous 8-12 weeks, especially clindamycin, fluoroquinolones, cephalosporins, carbapenems and broad-spectrum penicillins', 'Previous CDI episode', 'PPI/H2-blocker use when not clearly indicated', 'Inflammatory bowel disease', 'Immunosuppression, chemotherapy, transplantation or advanced comorbidity', 'Chronic kidney disease, hypoalbuminemia, severe underlying illness', 'Enteral feeding, abdominal surgery or gastrointestinal manipulation'],
          seasonality: 'None',
          transmission: 'Fecal-oral (spores), nosocomial transmission, hand hygiene!'
        },
        pathomechanism: {
          steps: [
            'Antibiotic treatment disrupts the normal gut flora, allowing C. difficile spores to germinate and multiply.',
            'The bacterium produces toxins: Toxin A (enterotoxin) causes fluid secretion and inflammation, while Toxin B (cytotoxin) directly damages intestinal epithelial cells.',
            'Severe inflammation and cell death lead to the formation of characteristic pseudomembranes on the colonic mucosa.'
          ],
          virulence_factors: ['Toxin A (TcdA)', 'Toxin B (TcdB)', 'Binary toxin (CDT)', 'Spore formation', 'Adherence factors']
        },
        clinical: {
          incubation: '2-10 days after AB, up to 8 weeks later',
          onset: 'Acute',
          symptoms: [
            { name: 'Watery diarrhea', description: 'New-onset unexplained diarrhea: usually >=3 unformed stools in 24 hours. Stools are typically watery and foul-smelling; blood is uncommon. Symptoms may start during antibiotics or within weeks after exposure.', severity: 'severe' },
            { name: 'Abdominal Pain', description: 'Diffuse, crampy abdominal pain and tenderness.', severity: 'moderate' },
            { name: 'Fever and systemic inflammation', description: 'Fever, leukocytosis, rising creatinine or hypoalbuminemia suggest severe disease; lactate elevation, shock or ileus suggest fulminant CDI.', severity: 'moderate' },
            { name: 'Colitis without diarrhea', description: 'In ileus or toxic megacolon diarrhea may decrease or disappear despite worsening disease; abdominal distension and systemic toxicity are red flags.', severity: 'severe' }
          ],
          physical_exam: [
            'Diffuse abdominal tenderness',
            'Distension',
            'Fever, tachycardia',
            'Signs of dehydration',
            'Severe: signs of ileus, toxic megacolon'
          ],
          complications: ['Fulminant colitis', 'Toxic megacolon', 'Ileus', 'Bowel perforation', 'Sepsis', 'Hypovolemic shock', 'Acute kidney injury', 'Death', 'Recurrence (20-30%; higher after each recurrence)']
        },
        diagnostics: {
          criteria: [
            { name: 'Who should be tested', items: ['Test only symptomatic patients with unexplained new-onset diarrhea (>=3 unformed stools/24 h), ileus or toxic megacolon.', 'Do not test formed stool, asymptomatic contacts, or for test-of-cure; NAAT can remain positive after clinical cure.', 'Review laxatives and enteral feeds before testing, but do not delay testing in severe or healthcare-associated diarrhea.'] },
            { name: 'Severity classification', items: ['Non-severe: WBC <=15 G/L and creatinine <1.5x baseline, no shock/ileus/megacolon.', 'Severe: WBC >15 G/L or creatinine >=1.5x baseline; albumin <30 g/L supports high-risk/severe disease.', 'Fulminant/severe-complicated: hypotension or shock, ileus, toxic megacolon, perforation, lactate elevation, peritonitis or rapidly deteriorating colitis.'] },
            { name: 'Preferred laboratory algorithm', items: ['Use a multistep stool algorithm: GDH antigen + toxin A/B EIA, with NAAT arbitration when discordant; or NAAT plus toxin testing when stool submission is restricted to clinically compatible cases.', 'GDH positive/toxin positive: CDI likely; treat according to severity.', 'NAAT positive/toxin negative: interpret with clinical probability; may be colonization, but treat if severe colitis or strong clinical suspicion.'] }
          ],
          laboratory: [
            { test: 'CBC', finding: 'Leukocytosis (up to >30 G/L)', interpretation: 'Marker of severity' },
            { test: 'Creatinine', finding: 'Elevated', interpretation: 'Severe CDI criterion (>1.5x baseline)' },
            { test: 'Albumin', finding: 'Decreased (<2.5 g/dL)', interpretation: 'Malnutrition, severity' },
            { test: 'Lactate', finding: 'Elevated', interpretation: 'Fulminant colitis' }
          ],
          imaging: [
            { modality: 'Abdominal X-ray', finding: 'Megacolon (>6cm)', significance: 'Toxic megacolon' },
            { modality: 'Abdominal CT', finding: 'Colonic wall thickening, accordion sign, ascites', significance: 'Severity assessment' }
          ],
          microbiology: [
            { test: 'Stool toxin (GDH + toxin A/B EIA)', finding: 'Positive', significance: 'Two-step algorithm' },
            { test: 'Stool PCR (NAAT)', finding: 'tcdB gene', significance: 'Most sensitive, but also detects colonization' },
            { test: 'Culture', finding: 'C. difficile isolation', significance: 'Typing, epidemiology' },
            { test: 'Sigmoidoscopy', finding: 'Pseudomembranes', significance: 'Not routine, diagnostic' }
          ]
        },
        calculators: [
          {
            name: 'ATLAS Score - C. difficile Outcome',
            items: [
              { label: 'Age 60-79 years', points: 1 },
              { label: 'Age ≥ 80 years', points: 2 },
              { label: 'Systemic antibiotic treatment during CDI therapy', points: 2 },
              { label: 'WBC 16-25 G/L', points: 1 },
              { label: 'WBC > 25 G/L', points: 2 },
              { label: 'Albumin 26-35 g/L', points: 1 },
              { label: 'Albumin ≤ 25 g/L', points: 2 },
              { label: 'Creatinine 121-179 µmol/L', points: 1 },
              { label: 'Creatinine ≥ 180 µmol/L', points: 2 }
            ],
            interpretation: [
              { min: 0, max: 2, text: '0-2 points: Low risk. 30-day mortality 0-5%.' },
              { min: 3, max: 5, text: '3-5 points: Moderate risk. 30-day mortality 10-20%.' },
              { min: 6, max: 10, text: '6-10 points: High risk. 30-day mortality >30%.' }
            ]
          }
        ],
        therapy: {
          empirical: {
            outpatient: [
              { drug: 'Fidaxomicin', dose: '2x200mg PO', duration: '10 days', note: 'First choice (less recurrence)' },
              { drug: 'Vancomycin', dose: '4x125mg PO', duration: '10 days', note: 'Alternative' }
            ],
            inpatient: [
              { drug: 'Vancomycin', dose: '4x125mg PO', duration: '10-14 days', note: 'If fidaxomicin is not available' },
              { drug: 'Fidaxomicin', dose: '2x200mg PO', duration: '10 days', note: 'Preferred' }
            ],
            icu: [
              { drug: 'Vancomycin', dose: '4x500mg PO + rectal', duration: '10-14 days', note: 'Fulminant: higher dose' },
              { drug: '+ Metronidazole', dose: '3x500mg IV', duration: '10-14 days', note: 'In case of ileus (IV penetration)' },
              { drug: 'Tigecycline', dose: '100 mg IV load, then 50 mg IV twice daily', duration: 'Individualized', note: 'Specialist option for refractory fulminant CDI in selected protocols' },
              { drug: 'Surgery', dose: 'Colectomy', duration: '', note: 'Toxic megacolon, perforation' }
            ]
          },
          targeted: 'Initial non-fulminant CDI: fidaxomicin preferred when available; oral vancomycin is an acceptable alternative. Metronidazole is reserved for situations where fidaxomicin/vancomycin are unavailable. Fulminant CDI: high-dose oral/NG +/- rectal vancomycin plus IV metronidazole, urgent surgical and infectious diseases review.',
          supportive: ['Stop the inciting antibiotic whenever clinically possible and narrow any ongoing systemic antibiotic therapy', 'Fluid, electrolyte and renal-function correction; monitor intake/output', 'Avoid antimotility agents and unnecessary opioids in severe/fulminant colitis', 'Assess daily for ileus, peritonitis, toxic megacolon, shock and rising lactate/WBC', 'Early surgical consultation for fulminant disease, megacolon, perforation or clinical deterioration'],
          prevention: ['Antibiotic stewardship and shortest effective systemic antibiotic course', 'Contact isolation with gloves/gown; dedicated toilet/commode', 'Soap-and-water hand hygiene after patient contact; alcohol alone is insufficient against spores', 'Sporicidal environmental cleaning', 'Review and discontinue unnecessary PPI/H2 blocker', 'Bezlotoxumab for selected high-risk patients to prevent recurrence', 'FMT/microbiota restoration after multiple recurrences according to local availability and safety screening'],
          guidelines: [
            'Initial CDI: fidaxomicin 200 mg PO twice daily for 10 days is preferred when feasible; vancomycin 125 mg PO four times daily for 10 days remains acceptable.',
            'First recurrence: fidaxomicin standard or extended-pulsed regimen is preferred; alternatives include vancomycin taper/pulse or a standard vancomycin course if metronidazole was used initially.',
            'Multiple recurrences: consider vancomycin taper/pulse, vancomycin followed by rifaximin, fidaxomicin, and FMT/microbiota-based therapy after appropriate antibiotic treatment.',
            'Bezlotoxumab 10 mg/kg IV once during antibacterial treatment can be added for recurrence within 6 months or high recurrence risk (age >=65, immunocompromise, severe CDI); use caution in heart failure.',
            'Fulminant CDI: vancomycin 500 mg PO/NG four times daily; add rectal vancomycin if ileus and metronidazole 500 mg IV every 8 h. Escalate early to surgery/ICU.',
            'Surgery: urgent evaluation for perforation, toxic megacolon, peritonitis, shock, organ failure, lactate rise or WBC >50 G/L; subtotal colectomy or diverting loop ileostomy with lavage may be considered locally.'
          ]
        },
        guidelines: {
          diagnosis: [
            'Suspicion: new onset diarrhea after antibiotic exposure or in nosocomial setting',
            'Lab: leukocytosis, elevated creatinine/ALP, decreased albumin are signs of severity',
            'Micro: two-step algorithm (GDH + toxin EIA) and/or NAAT; positive PCR alone may indicate colonization',
            'Endoscopy only in exceptional cases (pseudomembranes)'
          ],
          treatment_indications: [
            'Acute symptoms, especially severe presentation (leukocytosis >15 G/L, fever, creatinine elevation, jaundice, ileus or toxic megacolon)',
            'In recurrent patients, early intervention (consider bezlotoxumab, FMT)'
          ],
          first_line: [
            'Non-severe/severe: Fidaxomicin 200 mg twice daily for 10 days or Vancomycin 125 mg 4 times daily for 10 days',
            'Fulminant case: Oral/rectal Vancomycin higher dose + IV Metronidazole (in case of ileus)',
          ],
          supportive: [
            'Stopping the antibacterial agent if possible, fluid and electrolyte replacement, nutrition',
            'Avoid: antimotility agents in severe patients'
          ],
          monitoring: [
            'Monitoring clinical status, leukocytosis and renal function daily in severe cases',
            'In case of recurrence consider new drug treatment (e.g. fidaxomicin) or FMT'
          ],
          prevention: [
            'Antibiotic stewardship, hand hygiene, contact isolation, environmental disinfection (sporocidal agents)'
          ],
          special_populations: [
            'Elderly, immunosuppressed and hospitalized patients are at higher risk; lower threshold for early treatment in these'
          ],
          dosing: {
            adult: {
              fidaxomicin: '200 mg PO twice daily (BID) for 10 days',
              vancomycin: '125 mg PO 4x/day for 10 days (non-severe); in fulminant case 500 mg PO 4x/day + consider rectal administration',
              metronidazol_iv: '500 mg IV 3x/day (adjunctive in fulminant/ileus)'
            },
            pediatric: 'Pediatric doses according to local protocol; weight-based dosing of vancomycin required',
          },
        },
        differential: [
          { disease: 'Other AB-associated diarrhea', distinguishing: 'Toxin negative, milder' },
          { disease: 'Inflammatory bowel disease flare', distinguishing: 'History, endoscopy' },
          { disease: 'Ischemic colitis', distinguishing: 'Risk factors, CT angiography' },
          { disease: 'Other infectious enterocolitis', distinguishing: 'Stool culture, epidemiology' },
          { disease: 'Medication-induced diarrhea (e.g., laxatives, PPIs)', distinguishing: 'Medication history, resolution after stopping' }
        ],
        prognosis: {
          mortality: 'Overall 5-10%, Fulminant 30-50%',
          prognostic_scores: ['ATLAS score'],
          factors: 'Age, leukocytosis, albumin, creatinine, hypervirulent strain, delayed treatment'
        },
        references: [
          { text: 'IDSA/SHEA 2021 C. difficile guideline', url: 'https://www.idsociety.org/practice-guideline/clostridioides-difficile/' },
          { text: 'CDC C. difficile information', url: 'https://www.cdc.gov/cdiff/index.html' }
        ]
      },
      {
        id: 'salmonellosis',
        name: 'Salmonellosis (Non-typhoidal)',
        pathogen: { type: 'Bacterium', name: '<i>Salmonella enterica</i> (e.g., <i>Enteritidis, Typhimurium</i>)', gram: 'Gram-negative', shape: 'rod' },
        epidemiology: {
          incidence: 'Common food poisoning (more common in summer)',
          risk_groups: ['Infants', 'Elderly', 'Achlorhydria (PPI)', 'Immunosuppressed'],
          seasonality: 'Summer-autumn',
          transmission: 'Fecal-oral: contaminated food (eggs, poultry, meat), contact with reptiles'
        },
        pathomechanism: {
          steps: [
            'After ingestion (high bacterial load required), the pathogens survive gastric acid and reach the small intestine.',
            'In the small intestine, they enter Peyer\'s patches and deeper layers of the intestinal wall via M-cells.',
            'Bacterial multiplication triggers a strong inflammatory response, leading to neutrophil infiltration and fluid secretion.'
          ],
          virulence_factors: ['Type III secretion system (T3SS)', 'Enterotoxin']
        },
        clinical: {
          incubation: '6-72 hours (average 12-36 hours)',
          onset: 'Sudden',
          symptoms: [
            { name: 'Diarrhea', description: 'Sudden onset of profuse, watery, sometimes mucoid or bloody diarrhea. Characterized by nausea, vomiting, and diffuse abdominal pain.', severity: 'moderate' },
            { name: 'Fever', description: 'May be accompanied by high fever, chills, headache, and myalgia.', severity: 'moderate' },
            { name: 'Abdominal Cramps', description: 'Periumbilical or diffuse abdominal cramps.', severity: 'moderate' }
          ],
          physical_exam: ['Fever', 'Abdominal tenderness', 'Signs of dehydration'],
          complications: ['Bacteremia (5%, mainly elderly/immunosuppressed)', 'Septic arthritis', 'Osteomyelitis (sickle cell anemia)', 'Endovascular infection (aneurysm)']
        },
        diagnostics: {
          laboratory: [{ test: 'Inflammatory markers', finding: 'CRP elevated', interpretation: 'Bacterial origin' }],
          microbiology: [{ test: 'Stool culture', finding: 'Salmonella sp.', significance: 'Diagnostic' }]
        },
        differential: [
          { disease: 'Campylobacteriosis', distinguishing: 'Culture, similar clinical picture' },
          { disease: 'Shigellosis', distinguishing: 'Bloody-mucoid stool more common' },
          { disease: 'Viral gastroenteritis', distinguishing: 'Vomiting dominates, watery diarrhea' },
          { disease: 'IBD (Crohn\'s/Colitis)', distinguishing: 'Chronic, non-infectious, endoscopy' }
        ],
        therapy: {
          empirical: {
            outpatient: [{ drug: 'Supportive', dose: '-', duration: '-', note: 'Healthy adults do NOT need antibiotics (may prolong carriage!)' }],
            inpatient: [{ drug: 'Ceftriaxone', dose: '1-2g IV', duration: '7-14 days', note: 'In severe/invasive cases' }, { drug: 'Ciprofloxacin', dose: '2x500mg PO', duration: '7-10 days', note: 'Alternative (if susceptible)' }]
          },
          targeted: 'Only in risk groups (infant, elderly, immunosuppressed) or severe cases: Fluoroquinolone or Ceftriaxone.',
          supportive: ['Fluid replacement (ORS)', 'Probiotics'],
          prevention: ['Food hygiene', 'Thorough cooking of eggs/meat']
        },
        guidelines: {
          diagnosis: [
            'Suspicion: acute diarrhea with fever; higher risk for severe complications in infants/elderly/immunosuppressed',
            'Microbiology: stool culture for Salmonella identification; blood culture in severe or suspected sepsis cases'
          ],
          treatment_indications: [
            'Healthy adults, non-invasive infection: usually no antibiotics',
            'Antibiotics recommended: infants, elderly, immunosuppressed, sepsis, extraintestinal infection, pregnancy in certain situations'
          ],
          first_line: [
            'Severe/invasive case: Ceftriaxone IV or Fluoroquinolone (depending on susceptibility)'
          ],
          supportive: ['Fluid replacement, electrolyte replacement, nutrition'],
          prevention: ['Food safety, thorough cooking of eggs and poultry'],
          dosing: {
            adult: {
              ceftriaxone: '1–2 g IV once daily (usual course 5–14 days, depending on clinical status)',
              ciprofloxacin: '500 mg PO twice daily (7–10 days) – only for susceptible strains; local resistance must be considered'
            },
            pediatric: 'Ceftriaxone and fluoroquinolone pediatric doses are age and weight dependent; consult local pediatric protocol'
          },
        },
        prognosis: { mortality: 'Low (<1%), higher in sepsis', prognostic_scores: [], factors: 'Age, comorbidity' },
        references: [
          { text: 'CDC – Salmonella', url: 'https://www.cdc.gov/salmonella/index.html' },
          { text: 'WHO – Non-typhoidal Salmonella overview', url: 'https://www.who.int/news-room/fact-sheets/detail/salmonella-(non-typhoidal)' }
        ]
      },
      {
        id: 'shigellosis',
        name: 'Shigellosis (Dysentery)',
        pathogen: { type: 'Bacterium', name: '<i>Shigella (dysenteriae, flexneri, sonnei)</i>', gram: 'Gram-negative', shape: 'rod' },
        epidemiology: {
          incidence: 'Common worldwide, endemic in developing countries',
          risk_groups: ['Children (daycare, kindergarten)', 'Travelers', 'MSM'],
          transmission: 'Fecal-oral (person-to-person), very low infectious dose (10-100 bacteria)!'
        },
        pathomechanism: {
          steps: [
            'Bacteria invade colonic epithelial cells and spread from cell to cell, evading the immune system.',
            'Bacterial multiplication and produced toxins (e.g., Shiga toxin) cause mucosal necrosis, ulceration, and bleeding.',
            'Shiga toxin entering the bloodstream can damage renal endothelial cells, causing Hemolytic Uremic Syndrome (HUS).'
          ],
          virulence_factors: ['Shiga toxin (Stx)', 'Invasion plasmid antigens']
        },
        clinical: {
          incubation: '1-3 days',
          onset: 'Sudden',
          symptoms: [
            { name: 'Dysentery', description: 'Initially watery diarrhea, followed by classic dysentery: frequent, small-volume bloody-mucoid ("sputum-like") stools.', severity: 'severe' },
            { name: 'Tenesmus', description: 'Excruciating, painful, ineffective urge to defecate (straining). Pronounced toxic state.', severity: 'severe' },
            { name: 'Fever', description: 'Characterized by high fever and a toxic state.', severity: 'moderate' }
          ],
          complications: ['Hemolytic uremic syndrome (HUS - S. dysenteriae)', 'Toxic megacolon', 'Rectal prolapse', 'Reactive arthritis']
        },
        diagnostics: {
          laboratory: [{ test: 'CBC', finding: 'Leukocytosis, left shift', interpretation: 'Invasive infection' }],
          microbiology: [{ test: 'Stool culture', finding: 'Shigella sp.', significance: 'Diagnostic' }]
        },
        differential: [
          { disease: 'EIEC (E. coli)', distinguishing: 'Clinically identical, microbiology decides' },
          { disease: 'Amoebiasis', distinguishing: 'E. histolytica detection, less febrile' },
          { disease: 'Campylobacteriosis', distinguishing: 'Culture' },
          { disease: 'C. difficile', distinguishing: 'Antibiotic history, toxin test' }
        ],
        therapy: {
          empirical: {
            outpatient: [{ drug: 'Azithromycin', dose: '1x500mg PO', duration: '3 days', note: 'First choice' }, { drug: 'Ciprofloxacin', dose: '2x500mg PO', duration: '3 days', note: 'Alternative (resistance increasing)' }]
          },
          targeted: 'Antibiotics recommended to shorten illness and reduce infectivity. Azithromycin, Ceftriaxone, Ciprofloxacin.',
          supportive: ['Fluid replacement', 'Antimotility agents (Loperamide) are FORBIDDEN!'],
          prevention: ['Strict hand hygiene', 'Patient isolation']
        },
        guidelines: {
          diagnosis: [
            'Suspicion: bloody, mucoid stool and tenesmus; low infectious dose may suggest outbreak',
            'Microbiology: stool culture; Shiga-toxin test for S. dysenteriae'
          ],
          treatment_indications: [
            'Antibiotics recommended to shorten illness and reduce spread (especially in outbreaks, severe symptoms or risk groups)'
          ],
          first_line: [
            'Azithromycin (1 g single dose or 500 mg 3 days), Alternative: Ceftriaxone IV in severe cases'
          ],
          supportive: ['Fluid replacement, symptomatic treatment'],
          prevention: ['Regular hand hygiene, contact isolation, epidemic control measures'],
          dosing: {
            adult: {
              azithromycin: "1 g PO single dose or 500 mg PO 1x daily for 3 days (according to local protocol)",
              ciprofloxacin: '500 mg PO 2x/day for 3 days (Alternative; resistance increasing)',
              ceftriaxone: '1 g IV once daily in severe cases'
            },
            pediatric: 'Azithromycin and ceftriaxone pediatric doses are age and weight dependent; consult pediatric protocol'
          },
        },
        prognosis: { mortality: 'Low with treatment, S. dysenteriae type 1 in epidemics can be 20%', prognostic_scores: [], factors: 'Age, comorbidity, malnutrition' },
        references: [
          { text: 'CDC – Shigella', url: 'https://www.cdc.gov/shigella/index.html' },
          { text: 'WHO – Shigellosis factsheet', url: 'https://www.who.int/news-room/fact-sheets/detail/shigellosis' }
        ]
      },
      {
        id: 'campylobacter',
        name: 'Campylobacteriosis',
        pathogen: { type: 'Bacterium', name: '<i>Campylobacter jejuni</i>', gram: 'Gram-negative', shape: 'spiral/gull-wing' },
        epidemiology: {
          incidence: 'Most common bacterial gastroenteritis in the developed world',
          risk_groups: ['Infants', 'Young adults', 'Elderly'],
          seasonality: 'Summer',
          transmission: 'Contaminated poultry (undercooked), raw milk, water'
        },
        pathomechanism: {
          steps: [
            'Bacteria colonize and invade the mucosa of the small and large intestines.',
            'They produce toxins (e.g., CDT) that inhibit cell division and trigger inflammation.',
            'The infection can trigger Guillain-Barré syndrome via an autoimmune mechanism.'
          ],
          virulence_factors: ['Flagellum (motility)', 'Adhesins', 'Cytolethal distending toxin (CDT)']
        },
        clinical: {
          incubation: '2-5 days',
          onset: 'Sudden',
          symptoms: [
            { name: 'Diarrhea', description: 'Watery, often foul-smelling and bloody diarrhea.', severity: 'moderate' },
            { name: 'Abdominal Pain', description: 'Severe, crampy abdominal pain that can mimic appendicitis (pseudoappendicitis - RLQ pain). Complication: Guillain-Barré syndrome (ascending flaccid paralysis).', severity: 'severe' },
            { name: 'Fever', description: 'Diarrhea is often preceded by fever, headache, and myalgia.', severity: 'moderate' }
          ],
          physical_exam: ['Diffuse abdominal tenderness', 'Fever', 'Signs of dehydration'],
          complications: ['Guillain-Barré syndrome (GBS) - 1/1000 cases', 'Reactive arthritis', 'Erythema nodosum']
        },
        diagnostics: {
          laboratory: [{ test: 'CBC', finding: 'Leukocytosis', interpretation: 'Inflammation' }, { test: 'Stool', finding: 'Leukocytes, RBCs', interpretation: 'Invasive' }, { test: 'CRP', finding: 'Elevated', interpretation: 'Bacterial origin' }],
          microbiology: [{ test: 'Stool culture', finding: 'Campylobacter (special medium, 42°C)', significance: 'Diagnostic' }]
        },
        differential: [
          { disease: 'Salmonellosis', distinguishing: 'Culture, epidemiology' },
          { disease: 'Shigellosis', distinguishing: 'More severe dysentery, culture' },
          { disease: 'Appendicitis', distinguishing: 'US/CT, surgical consultation' }
        ],
        therapy: {
          empirical: {
            outpatient: [{ drug: 'Azithromycin', dose: '1x500mg PO', duration: '3 days', note: 'First choice in severe cases' }]
          },
          targeted: 'Mild cases only fluid replacement. Severe cases: macrolides (Azithromycin). Fluoroquinolone resistance is high!',
          supportive: ['Fluid replacement'],
          prevention: ['Proper cooking of poultry', 'Avoid cross-contamination in the kitchen']
        },
        guidelines: {
          diagnosis: [
            'Suspicion: acute abdominal pain, bloody diarrhea; pseudoappendicitis symptoms possible',
            'Microbiology: stool culture under special conditions (42°C); antigen/PCR where available'
          ],
          treatment_indications: [
            'Mild, non-systemic case: supportive treatment only',
            'Severe or persistent symptoms, immunosuppressed: macrolide therapy recommended'
          ],
          first_line: ['Azithromycin 500 mg single dose or 500 mg daily for 3 days (in more severe cases)'],
          supportive: ['Fluid replacement, electrolyte replacement'],
          prevention: ['Thorough cooking of poultry, kitchen hygiene'],
          dosing: {
            adult: {
              azithromycin: '500 mg PO single dose or 500 mg PO once daily for 3 days (alternative regimen: 500 mg day 1, then 250 mg daily 2–3) ',
              ciprofloxacin: '500 mg PO twice daily for 3 days (if susceptible and severe case)'
            },
            pediatric: 'Macrolide pediatric doses are age and weight dependent; request local protocol'
          },
        },
        prognosis: { mortality: 'Very low (<0.1%)', prognostic_scores: [], factors: 'GBS complication can be severe, reactive arthritis prolonged' },
        references: [
          { text: 'CDC – Campylobacter', url: 'https://www.cdc.gov/campylobacter/index.html' },
          { text: 'ESCMID guidance on Campylobacter', url: 'https://www.escmid.org/' }
        ]
      },
      {
        id: 'ecoli_enteritis',
        name: 'E. coli enteritis (ETEC, EHEC, EPEC, EIEC)',
        pathogen: { type: 'Bacterium', name: '<i>Escherichia coli</i> (pathogenic strains)', gram: 'Gram-negative', shape: 'rod' },
        epidemiology: {
          incidence: 'ETEC: traveler\'s diarrhea; EHEC: foodborne outbreaks; EPEC: infantile diarrhea; EIEC: dysentery-like',
          risk_groups: ['Travelers (ETEC)', 'Children, elderly (EHEC)', 'Infants (EPEC)'],
          seasonality: 'Summer',
          transmission: 'Fecal-oral, contaminated water/food (beef, vegetables)'
        },
        pathomechanism: {
          steps: [
            'ETEC: Bacteria adhere in the small intestine and produce enterotoxins, causing massive fluid secretion.',
            'EHEC: Produce Shiga toxin in the large intestine, causing bloody diarrhea and potentially renal failure (HUS) upon systemic absorption.',
            'EPEC/EIEC: Adhere to or invade intestinal epithelial cells, causing mucosal damage and inflammation.'
          ],
          virulence_factors: ['Enterotoxins', 'Shiga-toxin (Stx1, Stx2)', 'Adhesins (EPEC)', 'Invasins (EIEC)']
        },
        clinical: {
          incubation: 'ETEC/EPEC: 1-3 days; EHEC/EIEC: 3-4 days',
          onset: 'Sudden',
          symptoms: [
            { name: 'Watery Diarrhea (ETEC/EPEC)', description: 'Sudden onset of profuse watery diarrhea, without fever (traveler\'s diarrhea).', severity: 'moderate' },
            { name: 'Bloody Diarrhea (EHEC/EIEC)', description: 'In EHEC: sudden onset watery, then massively bloody diarrhea (hemorrhagic colitis) WITHOUT fever. Marked abdominal cramping. Complication: HUS.', severity: 'severe' }
          ],
          physical_exam: ['Dehydration', 'Abdominal tenderness (EHEC/EIEC: marked)', 'Fever (common in EIEC, rare in EHEC)'],
          complications: ['Hemolytic uremic syndrome (HUS) - 5-10% after EHEC infection (mainly children)', 'TTP (adults)', 'Malnutrition (EPEC)']
        },
        diagnostics: {
          laboratory: [{ test: 'CBC', finding: 'Thrombocytopenia, anemia', interpretation: 'Suspicion of HUS!' }, { test: 'Renal function', finding: 'Creatinine elevation', interpretation: 'HUS' }],
          microbiology: [
            { test: 'Stool culture', finding: 'Sorbitol-MacConkey (EHEC)', significance: 'EHEC screening' },
            { test: 'Shiga-toxin detection', finding: 'PCR or EIA', significance: 'EHEC diagnosis' },
            { test: 'PCR panel', finding: 'Virulence genes', significance: 'Differentiation of EPEC/EIEC/ETEC' }
          ]
        },
        differential: [
          { disease: 'Shigellosis', distinguishing: 'EIEC clinically identical, culture decides' },
          { disease: 'Campylobacteriosis', distinguishing: 'Culture, GBS risk' },
          { disease: 'TTP', distinguishing: 'Adults, neurological symptoms, ADAMTS13' }
        ],
        therapy: {
          empirical: {
            outpatient: [
              { drug: 'ETEC: Rifaximin', dose: '2x200mg PO', duration: '3 days', note: 'Traveler\'s diarrhea' },
              { drug: 'EHEC: ANTIBIOTICS CONTRAINDICATED!', dose: '-', duration: '-', note: 'Increases risk of HUS (toxin release)!' },
              { drug: 'EIEC: Ciprofloxacin/Azithromycin', dose: 'Standard dose', duration: '3 days', note: 'Severe cases (like Shigella)' }
            ]
          },
          targeted: 'ETEC/EIEC: Ciprofloxacin or Azithromycin (in severe cases). EHEC: ONLY supportive! EPEC: Supportive.',
          supportive: ['Fluid replacement', 'In HUS: dialysis, transfusion'],
          prevention: ['Food hygiene', 'Thorough cooking of beef', 'Travelers: bottled water']
        },
        guidelines: {
          diagnosis: [
            'Suspicion: bloody diarrhea (EHEC/EIEC) or watery diarrhea (ETEC/EPEC); exclusion of HUS is important',
            'Microbiology: EHEC screening, PCR panel to differentiate pathotypes'
          ],
          treatment_indications: [
            'In EHEC infection antibiotics are generally contraindicated (increases HUS risk)',
            'In ETEC/EIEC antibiotics may be given for severe symptoms'
          ],
          supportive: ['Fluid replacement, close monitoring; in HUS nephrological care, dialysis if needed'],
          prevention: ['Food hygiene, well-cooked beef, precautions for travelers'],
          dosing: {
            adult: {
              rifaximin: '200 mg PO 3 times daily for 3 days (ETEC, non-invasive traveler\'s diarrhea)',
              azithromycin: '1 g PO single dose or 500 mg PO once daily for 1–3 days (severe ETEC/EIEC)'
            },
            pediatric: 'Rifaximin pediatric doses limited; avoid antibiotics in children with EHEC'
          },
        },
        prognosis: { mortality: 'ETEC/EPEC: low; EHEC: 3-5% mortality in HUS', prognostic_scores: [], factors: 'Age (child/elderly), development of HUS, antibiotic use (worsens EHEC!)' },
        references: [
          { text: 'CDC – E. coli (STEC)', url: 'https://www.cdc.gov/ecoli/index.html' },
          { text: 'CDC – Traveler\'s Diarrhea & Rifaximin', url: 'https://www.cdc.gov/antibiotic-use/community/for-hcp/common-conditions/travelers-diarrhea.html' }
        ]
      },
      {
        id: 'yersiniosis',
        name: 'Yersiniosis',
        pathogen: { type: 'Bacterium', name: '<i>Yersinia enterocolitica</i>', gram: 'Gram-negative', shape: 'coccobacillus' },
        epidemiology: {
          incidence: 'More common in temperate climates, in winter',
          risk_groups: ['Children', 'Iron overload patients (hemochromatosis)'],
          seasonality: 'Winter',
          transmission: 'Raw pork, milk, contaminated water. Psychrophilic (grows in refrigerator!)'
        },
        pathomechanism: {
          steps: [
            'Bacteria enter Peyer\'s patches and mesenteric lymph nodes via M-cells in the ileum.',
            'They cause inflammation and microabscesses in the lymph nodes (mesenteric lymphadenitis).',
            'The infection can trigger reactive arthritis via immunological mechanisms.'
          ],
          virulence_factors: ['Yersinia outer proteins (Yops)', 'T3SS', 'Invasin']
        },
        clinical: {
          incubation: '4-7 days',
          onset: 'Gradual',
          symptoms: [
            { name: 'Enterocolitis', description: 'Fever, diarrhea (possibly bloody), vomiting.', severity: 'moderate' },
            { name: 'Pseudoappendicitis', description: 'Right lower quadrant pain and tenderness mimicking appendicitis.', severity: 'moderate' }
          ],
          physical_exam: ['Right lower quadrant tenderness', 'Fever', 'Erythema nodosum (late)'],
          complications: ['Reactive arthritis (HLA-B27)', 'Erythema nodosum', 'Sepsis (in iron overload patients)']
        },
        diagnostics: {
          laboratory: [{ test: 'Inflammatory markers', finding: 'Elevated', interpretation: 'Bacterial' }],
          imaging: [{ modality: 'Abdominal US', finding: 'Mesenteric lymphadenopathy, terminal ileitis', significance: 'Exclusion of appendicitis' }],
          microbiology: [{ test: 'Stool culture', finding: 'CIN agar (cold enrichment)', significance: 'Must be requested from the lab' }]
        },
        differential: [
          { disease: 'Appendicitis', distinguishing: 'US/CT, surgical consultation' },
          { disease: 'Crohn\'s disease', distinguishing: 'Chronic, endoscopy, biopsy' },
          { disease: 'Other bacterial enteritis', distinguishing: 'Culture' }
        ],
        therapy: {
          empirical: {
            outpatient: [{ drug: 'Supportive', dose: '-', duration: '-', note: 'Usually self-limiting' }],
            inpatient: [{ drug: 'Ciprofloxacin', dose: '2x500mg PO', duration: '7-10 days', note: 'In severe cases' }, { drug: 'Doxycycline', dose: '2x100mg PO', duration: '7-10 days', note: 'Alternative' }]
          },
          targeted: 'Fluoroquinolones, Doxycycline, TMP-SMX. Sepsis: Ceftriaxone.',
          prevention: ['Avoid raw pork', 'Pasteurization of milk']
        },
        guidelines: {
          diagnosis: [
            'Suspicion: right lower quadrant pain, fever, occasionally bloody diarrhea; pseudoappendicitis picture possible',
            'Microbiology: stool culture on CIN agar, notify lab about need for cold enrichment'
          ],
          treatment_indications: [
            'Usually self-limiting, antibiotics only for severe systemic symptoms, systemic spread or iron overload patients'
          ],
          first_line: ['Severe case: Ciprofloxacin or Doxycycline (considering local resistance)'],
          supportive: ['Fluid replacement, antipyretics'],
          prevention: ['Education: avoid raw pork, consume pasteurized milk'],
          dosing: {
            adult: {
              ciprofloxacin: '500 mg PO twice daily for 7–10 days',
              doxycycline: '100 mg PO twice daily for 7–10 days'
            },
            pediatric: 'In children usually symptomatic treatment; antibiotics only in severe, systemic infection (pediatric consultation)'
          },
        },
        prognosis: { mortality: 'Low, but high in sepsis (50%)', prognostic_scores: [], factors: 'Iron overload, immunosuppression, late diagnosis' },
        references: [
          { text: 'CDC – Yersinia enterocolitica', url: 'https://www.cdc.gov/yersinia/index.html' }
        ]
      },
      {
        id: 'giardiasis',
        name: 'Giardiasis',
        pathogen: { type: 'Protozoan', name: '<i>Giardia duodenalis (lamblia)</i>', gram: '-', shape: 'pear-shaped (trophozoite)' },
        epidemiology: {
          incidence: 'Widespread worldwide, most common parasitic intestinal infection',
          risk_groups: ['Children', 'Campers (stream water)', 'IgA deficient individuals'],
          seasonality: 'Summer-autumn',
          transmission: 'Fecal-oral (cysts), water (chlorine-resistant!), food'
        },
        pathomechanism: {
          steps: [
            'Trophozoites are released from ingested cysts in the duodenum.',
            'Parasites attach to the villi of the small intestine with their sucking discs but do not invade tissues.',
            'Damage to intestinal villi and deficiency of disaccharidase enzymes cause malabsorption and osmotic diarrhea.'
          ]
        },
        clinical: {
          incubation: '1-3 weeks',
          onset: 'Gradual',
          symptoms: [
            { name: 'Diarrhea', description: 'Prolonged, foul-smelling, greasy, non-bloody diarrhea.', severity: 'moderate' },
            { name: 'Bloating', description: 'Marked gas production, abdominal bloating, sulfurous burping.', severity: 'moderate' },
            { name: 'Weight Loss', description: 'Significant weight loss may occur due to malabsorption.', severity: 'moderate' }
          ],
          physical_exam: ['Meteorism', 'Diffuse abdominal tenderness', 'No fever'],
          complications: ['Chronic diarrhea', 'Malabsorption (vitamin deficiency)', 'Failure to thrive (children)']
        },
        diagnostics: {
          laboratory: [{ test: 'CBC', finding: 'Normal, NO eosinophilia', interpretation: 'Non-invasive parasite' }],
          microbiology: [
            { test: 'Stool parasite exam', finding: 'Cysts or trophozoites', significance: '3 samples needed (intermittent shedding)' },
            { test: 'Stool antigen (EIA)', finding: 'Positive', significance: 'More sensitive than microscopy' }
          ]
        },
        differential: [
          { disease: 'Lactose intolerance', distinguishing: 'Breath test, effect of diet' },
          { disease: 'IBS', distinguishing: 'Chronic, negative parasite test' },
          { disease: 'Cryptosporidiosis', distinguishing: 'Acid-fast stain, immunosuppression' }
        ],
        therapy: {
          empirical: {
            outpatient: [
              { drug: 'Metronidazole', dose: '3x250mg PO', duration: '5-7 days', note: 'First choice' },
              { drug: 'Tinidazole', dose: '2g PO', duration: 'Single dose', note: 'More convenient' }
            ]
          },
          targeted: 'Nitroimidazoles (Metronidazole, Tinidazole). In pregnancy: Paromomycin.',
          prevention: ['Boil/filter water (chlorine is not enough!)', 'Hand washing']
        },
        guidelines: {
          diagnosis: [
            'Investigation of chronic/acute loose stool: 3 stool samples for parasite exam or antigen test (EIA) for faster result',
            'Eosinophilia usually absent, breath tests for differential diagnosis'
          ],
          treatment_indications: [
            'All symptomatic cases should be treated; asymptomatic carriage only treated in special epidemiological indication'
          ],
          first_line: ['Metronidazole 250–750 mg 3x daily 5–7 days or Tinidazole 2 g single dose (according to local protocol)'],
          supportive: ['Fluid replacement, diet (avoid fatty foods)'],
          prevention: ['Boil/filter drinking water, hand hygiene; hygiene measures in child communities'],
          dosing: {
            adult: {
              metronidazole: '250–500 mg PO 3 times daily for 5–7 days (many protocols 500 mg 2–3 times daily)',
              tinidazole: '2 g PO single dose (single dose effective alternative)'
            },
            pregnancy: 'In pregnancy: Paromomycin 500 mg PO 3 times daily for 7 days preferred (avoid metronidazole/tinidazole in first trimester)',
            pediatric: 'Pediatric doses age and weight dependent; tinidazole/metronidazole pediatric dosing according to local protocol'
          },
        },
        prognosis: { mortality: 'Excellent, but can become chronic without treatment', prognostic_scores: [], factors: 'IgA deficiency, reinfection' },
        references: [
          { text: 'CDC – Giardiasis', url: 'https://www.cdc.gov/parasites/giardia/index.html' }
        ]
      },
      {
        id: 'amoebiasis',
        name: 'Amoebiasis',
        pathogen: { type: 'Protozoan', name: '<i>Entamoeba histolytica</i>', gram: '-', shape: 'amoeboid' },
        epidemiology: {
          incidence: 'Endemic in tropical/subtropical areas',
          risk_groups: ['Travelers', 'Immigrants', 'Institutionalized individuals', 'MSM'],
          seasonality: 'None',
          transmission: 'Fecal-oral (cysts)'
        },
        pathomechanism: {
          steps: [
            'Trophozoites develop from ingested cysts in the large intestine and invade the mucosa.',
            'Parasites produce tissue-dissolving enzymes, creating characteristic flask-shaped ulcers.',
            'Entering the bloodstream, parasites can reach the liver and form abscesses.'
          ]
        },
        clinical: {
          incubation: '2-4 weeks',
          onset: 'Gradual',
          symptoms: [
            { name: 'Amoebic Dysentery', description: 'Bloody, mucoid diarrhea with abdominal pain.', severity: 'severe' },
            { name: 'Amoebic Liver Abscess', description: 'Right upper quadrant pain, fever, weight loss, even without diarrhea.', severity: 'severe' }
          ],
          physical_exam: ['Abdominal tenderness (cecum/colon)', 'Hepatomegaly, liver percussion tenderness (abscess)'],
          complications: ['Bowel perforation', 'Toxic megacolon', 'Abscess rupture (pleura, peritoneum, pericardium)', 'Brain abscess']
        },
        diagnostics: {
          laboratory: [{ test: 'CBC', finding: 'Leukocytosis (in abscess)', interpretation: 'Inflammation' }, { test: 'Liver enzymes', finding: 'ALP elevated', interpretation: 'Abscess' }],
          microbiology: [
            { test: 'Stool parasite exam', finding: 'Trophozoites (with RBCs in cytoplasm!)', significance: 'Must be distinguished from E. dispar' },
            { test: 'Stool antigen/PCR', finding: 'E. histolytica specific', significance: 'Gold standard' },
            { test: 'Serology', finding: 'Positive', significance: 'Useful in invasive disease (liver abscess)' }
          ],
          imaging: [{ modality: 'Abdominal US/CT', finding: 'Solitary liver abscess (right lobe)', significance: 'Liver abscess diagnosis' }]
        },
        differential: [
          { disease: 'Bacterial dysentery', distinguishing: 'Culture, fever more common' },
          { disease: 'Pyogenic liver abscess', distinguishing: 'Bacterial culture, more septic' },
          { disease: 'Echinococcus cyst', distinguishing: 'Serology, imaging (daughter cysts)' }
        ],
        therapy: {
          empirical: {
            outpatient: [
              { drug: 'Metronidazole', dose: '3x750mg PO', duration: '7-10 days', note: 'Tissue agent (invasive)' },
              { drug: '+ Paromomycin', dose: '3x500mg PO', duration: '7 days', note: 'Luminal agent (against cyst shedding) - MANDATORY addition!' }
            ]
          },
          targeted: 'Metronidazole (tissue) + Paromomycin/Diloxanide (luminal). Liver abscess: Metronidazole + drainage if needed.',
          prevention: ['Water and food hygiene']
        },
        guidelines: {
          diagnosis: [
            'In suspicion of dysentery stool parasite exam, antigen/PCR for rapid and specific diagnosis',
            'In liver abscess imaging (US/CT) and serology help diagnosis'
          ],
          treatment_indications: [
            'Invasive amoebic dysentery or liver abscess: Metronidazole or Tinidazole (tissue treatment) mandatory, then luminal agent (Paromomycin/Diloxanide) to eliminate cysts',
            'Mild luminal infection: Paromomycin/diloxanide alone'
          ],
          first_line: ['Metronidazole 750 mg 3x daily 7–10 days + Paromomycin 500 mg 3x daily 7 days (luminal supplement)'],
          supportive: ['Fluid replacement, analgesia, nutrition; in liver abscess consider drainage indication'],
          prevention: ['Water and food hygiene, hand washing, precautions for travelers'],
          dosing: {
            adult: {
              metronidazole: '750 mg PO 3 times daily for 7–10 days (invasive/abscess)',
              tinidazole: '2 g PO once daily for 3 days (alternative tissue treatment according to local protocol)',
              paromomycin: '500 mg PO 3 times daily for 7 days (luminal supplement)'
            },
            pregnancy: 'In pregnancy avoid tinidazole/metronidazole in first trimester; paromomycin preferred for luminal treatment',
            pediatric: 'Pediatric dose according to local protocol; pediatric consultation recommended'
          },
        },
        prognosis: { mortality: 'Good with treatment (<1%), higher with complicated abscess/perforation', prognostic_scores: [], factors: 'Late diagnosis, abscess rupture' },
        references: [
          { text: 'CDC – Amebiasis', url: 'https://www.cdc.gov/parasites/amebiasis/index.html' },
          { text: 'WHO – Amebiasis', url: 'https://www.who.int/health-topics/amebiasis' }
        ]
      },
      {
        id: 'cryptosporidiosis',
        name: 'Cryptosporidiosis',
        pathogen: { type: 'Protozoan', name: '<i>Cryptosporidium hominis/parvum</i>', gram: 'Acid-fast stain', shape: 'oocyst' },
        epidemiology: {
          incidence: 'Common waterborne outbreaks (swimming pools)',
          risk_groups: ['AIDS patients (defining opportunist)', 'Children', 'Veterinarians'],
          seasonality: 'Summer-autumn',
          transmission: 'Fecal-oral, water (chlorine-resistant oocysts!)'
        },
        pathomechanism: {
          steps: [
            'After ingestion of oocysts, sporozoites attach to the surface of small intestinal epithelial cells (intracellular but extracytoplasmic).',
            'Infection causes villus atrophy and crypt hyperplasia.',
            'This leads to severe malabsorption and secretory diarrhea.'
          ],
          virulence_factors: ['Adhesins', 'Proteases']
        },
        clinical: {
          incubation: '7-10 days',
          onset: 'Sudden',
          symptoms: [
            { name: 'Watery Diarrhea', description: 'Profuse, watery diarrhea with abdominal cramps.', severity: 'moderate' },
            { name: 'Persistent Diarrhea', description: 'In immunosuppressed patients (e.g., AIDS), diarrhea can become chronic and cause severe fluid loss.', severity: 'severe' }
          ],
          physical_exam: ['Signs of dehydration', 'Cachexia (in chronic cases)'],
          complications: ['Severe dehydration', 'Malnutrition', 'Biliary tract involvement (AIDS)']
        },
        diagnostics: {
          laboratory: [{ test: 'CD4 count', finding: '<100/µL', interpretation: 'Risk of severe course (HIV)' }],
          microbiology: [
            { test: 'Stool stain', finding: 'Acid-fast oocysts (modified Z-N)', significance: 'On special request' },
            { test: 'Stool antigen/PCR', finding: 'Positive', significance: 'More sensitive' }
          ]
        },
        differential: [
          { disease: 'Giardiasis', distinguishing: 'Stool exam, bloating dominates' },
          { disease: 'Isosporiasis', distinguishing: 'Larger oocysts, TMP-SMX effective' },
          { disease: 'Microsporidiosis', distinguishing: 'Smaller spores, special stain' }
        ],
        therapy: {
          empirical: {
            outpatient: [
              { drug: 'Nitazoxanide', dose: '2x500mg PO', duration: '3 days', note: 'For immunocompetent' },
              { drug: 'ART (Antiretroviral therapy)', dose: '-', duration: '-', note: 'Restoring the immune system is key in HIV patients!' }
            ]
          },
          targeted: 'Immunocompetent: Nitazoxanide. Immunosuppressed: ART optimization, supportive, Nitazoxanide (less effective).',
          supportive: ['Fluid replacement', 'Antimotility agents (with caution)'],
          prevention: ['Water filtration (<1 micron), avoid swimming pools during diarrhea']
        },
        guidelines: {
          diagnosis: [
            'Suspicion: persistent watery diarrhea in immunosuppressed patient (CD4<100), in waterborne outbreaks',
            'Diagnosis: stool antigen or PCR; acid-fast stain on special request'
          ],
          treatment_indications: [
            'Immunocompetent: often heals spontaneously',
            'Immunodeficient: antiviral/therapeutic intervention required; ART optimization priority'
          ],
          first_line: ['Nitazoxanide for immunocompetent patients; in immunosuppressed primarily restoration of immunocompetence (ART)'],
          supportive: ['Fluid and nutritional supplementation, electrolyte monitoring'],
          prevention: ['Filter/boil drinking water, personal hygiene, avoid swimming pool in case of diarrhea'],
          dosing: {
            adult: {
              nitazoxanide_immunocompetent: '500 mg PO twice daily for 3 days',
              nitazoxanide_immunocompromised: 'Consider longer course (local protocol); ART optimization primary'
            },
            pediatric: 'Nitazoxanide pediatric dose according to age and weight; request local protocol'
          },
        },
        prognosis: { mortality: 'Immunocompetent: good; AIDS: high mortality with CD4<100', prognostic_scores: [], factors: 'Restoration of immune status (ART)' },
        references: [
          { text: 'CDC – Cryptosporidium', url: 'https://www.cdc.gov/parasites/crypto/index.html' },
          { text: 'WHO – Cryptosporidiosis', url: 'https://www.who.int/news-room/fact-sheets/detail/cryptosporidiosis' }
        ]
      },
      {
        id: 'viral_gastroenteritis',
        name: 'Viral Gastroenteritis',
        pathogen: { type: 'Virus', name: '<i>Rotavirus, Norovirus, Adenovirus, Astrovirus</i>', gram: 'RNA/DNA', shape: 'variable' },
        epidemiology: {
          incidence: 'Norovirus: most common epidemic GE (all ages); Rotavirus: infants (before vaccine)',
          risk_groups: ['Infants (Rota)', 'Elderly (Noro)', 'Closed communities (ships, barracks)'],
          seasonality: 'Winter (Rota, Noro)',
          transmission: 'Fecal-oral, aerosol (vomiting - Noro), fomites'
        },
        pathomechanism: {
          steps: [
            'Viruses replicate in the epithelial cells of small intestinal villi, destroying them.',
            'Shortening of villi reduces the absorptive surface and digestive enzymes.',
            'Unabsorbed nutrients draw water into the intestinal lumen (osmotic diarrhea).'
          ],
          virulence_factors: ['Capsid stability', 'NSP4 (Rota)']
        },
        clinical: {
          incubation: '12-48 hours (Noro), 1-3 days (Rota)',
          onset: 'Sudden',
          symptoms: [
            { name: 'Vomiting', description: 'Sudden, repeated vomiting (especially with Norovirus).', severity: 'severe' },
            { name: 'Watery Diarrhea', description: 'Large volume watery stools accompanied by fever and myalgia.', severity: 'moderate' }
          ],
          physical_exam: ['Signs of dehydration (dry tongue, decreased turgor)', 'Diffuse abdominal tenderness'],
          complications: ['Severe dehydration (infants, elderly)', 'Electrolyte imbalances']
        },
        diagnostics: {
          laboratory: [{ test: 'Electrolytes', finding: 'Imbalances', interpretation: 'Dehydration' }, { test: 'CBC', finding: 'Normal', interpretation: 'Not bacterial' }],
          microbiology: [
            { test: 'Stool antigen (Rota/Adeno)', finding: 'Positive', significance: 'Rapid test in children' },
            { test: 'PCR', finding: 'Norovirus', significance: 'For epidemiological purposes' }
          ]
        },
        differential: [
          { disease: 'Bacterial gastroenteritis', distinguishing: 'Fever, bloody stool, culture' },
          { disease: 'Food poisoning (toxin)', distinguishing: 'Shared meal, shorter incubation' },
          { disease: 'Drug side effect', distinguishing: 'History' }
        ],
        therapy: {
          empirical: {
            outpatient: [{ drug: 'None', dose: '-', duration: '-', note: 'Antibiotics are ineffective!' }]
          },
          targeted: 'No specific antiviral agent.',
          supportive: ['Oral rehydration (ORS) - crucial!', 'Antiemetics (Ondansetron)', 'Probiotics (Lactobacillus GG, S. boulardii)'],
          prevention: ['Rotavirus vaccine (infants)', 'Hand washing (alcohol gel less effective against Norovirus!)', 'Isolation']
        },
        guidelines: {
          diagnosis: [
            'Suspicion: symptom complex with vomiting and/or watery diarrhea, frequent outbreaks in closed communities',
            'Lab: primarily assessment of fluid and electrolyte status; virus confirmation by PCR/antigen test for epidemiological purposes'
          ],
          treatment_indications: [
            'Mostly only supportive treatment needed; hospitalization in case of dehydration, severe vomiting or infants/elderly'
          ],
          first_line: ['Oral rehydration ORS, in severe vomiting antiemetic (ondansetron also applicable in children according to local protocol)'],
          supportive: ['Fluid replacement, electrolyte correction, nutrition'],
          prevention: ['Rotavirus vaccination for infants, hand hygiene, isolation in outbreaks; in Norovirus disinfection of fomites'],
          dosing: {
            vaccination: {
              rotavirus: 'Rotavirus vaccine: according to local vaccination schedule (e.g. Rotarix 2 doses, RotaTeq 3 doses – see vaccination protocol)'
            }
          },
        },
        prognosis: { mortality: 'Very low in developed countries, dehydration is the main danger', prognostic_scores: [], factors: 'Age (infant/elderly), comorbidity' },
        references: [
          { text: 'CDC – Norovirus', url: 'https://www.cdc.gov/norovirus/index.html' },
          { text: 'CDC – Rotavirus', url: 'https://www.cdc.gov/rotavirus/index.html' }
        ]
      },
      {
        id: 'cholera',
        name: 'Cholera',
        pathogen: { type: 'Bacterium', name: '<i>Vibrio cholerae</i> (O1, O139)', gram: 'Gram-negative', shape: 'curved rod (vibrio)' },
        epidemiology: {
          incidence: 'Endemic (Asia, Africa, Haiti), epidemic',
          risk_groups: ['People in extreme poverty', 'Victims of natural disasters', 'Travelers (rare)'],
          seasonality: 'Rainy season',
          transmission: 'Fecal-oral (contaminated water/food)'
        },
        pathomechanism: {
          steps: [
            'Bacteria adhering in the small intestine produce cholera toxin.',
            'The toxin activates adenylate cyclase, leading to increased cAMP levels.',
            'This causes massive efflux of chloride ions and water into the intestinal lumen, leading to severe, life-threatening diarrhea.'
          ],
          virulence_factors: ['Cholera toxin (AB5 toxin)', 'Toxin-coregulated pilus (TCP)']
        },
        clinical: {
          incubation: 'A few hours - 5 days',
          onset: 'Sudden',
          symptoms: [
            { name: 'Rice-water Stool', description: 'Painless, large volume diarrhea resembling rice water.', severity: 'severe' },
            { name: 'Dehydration', description: 'Rapidly developing severe dehydration, muscle cramps, shock.', severity: 'severe' }
          ],
          physical_exam: [
            'Severe dehydration (hypovolemic shock)',
            'Dry mucous membranes, decreased turgor',
            'Washerwoman\'s hands (wrinkled skin)',
            'Hypotension, tachycardia',
            'Fever is usually ABSENT'
          ],
          complications: ['Hypovolemic shock', 'Acute renal failure (ATN)', 'Severe hypokalemia', 'Metabolic acidosis', 'Death (50% if untreated!)']
        },
        diagnostics: {
          laboratory: [
            { test: 'CBC', finding: 'Hemoconcentration', interpretation: 'Dehydration' },
            { test: 'Electrolytes', finding: 'Hypokalemia, acidosis', interpretation: 'Loss' },
            { test: 'Renal function', finding: 'Prerenal failure', interpretation: 'Volume depletion' }
          ],
          microbiology: [
            { test: 'Stool culture', finding: 'TCBS agar (yellow colonies)', significance: 'Gold standard' },
            { test: 'Rapid test (RDT)', finding: 'Crystal VC', significance: 'In outbreaks' },
            { test: 'Dark-field microscopy', finding: 'Shooting star motility', significance: 'Rapid' }
          ]
        },
        differential: [
          { disease: 'ETEC', distinguishing: 'Travel, less severe' },
          { disease: 'Viral gastroenteritis', distinguishing: 'Vomiting may dominate, less severe dehydration' }
        ],
        therapy: {
          empirical: {
            outpatient: [
              { drug: 'Doxycycline', dose: '300mg PO', duration: 'Single dose', note: 'For adults' },
              { drug: 'Azithromycin', dose: '1g PO', duration: 'Single dose', note: 'Pregnant women, children' }
            ]
          },
          targeted: 'Fluid replacement is most important! Antibiotics are only adjunctive (shorten the illness).',
          supportive: ['ORS (Oral Rehydration Solution) - WHO formula', 'IV Ringer\'s lactate (severe dehydration)'],
          prevention: ['Clean water, hygiene', 'Oral cholera vaccine (Dukoral, Shanchol)']
        },
        guidelines: {
          diagnosis: [
            'Suspicion: large volume, painless "rice water" diarrhea; high probability in epidemic context',
            'Lab: fluid and electrolyte status especially important; culture on TCBS agar for epidemiological identification'
          ],
          treatment_indications: [
            'Immediate rehydration in any severe or large volume dystrophic diarrhea; antibiotics to shorten illness in severe cases'
          ],
          first_line: [
            'General: ORS and intravenous volume replacement in severe dehydration',
            'Antibiotic: Doxycycline single 300 mg for adults, or Azithromycin 1 g for pregnant women/children (according to local guidelines)'
          ],
          supportive: ['Electrolyte replacement, monitoring (kidney, potassium), oxygen and circulatory support if needed'],
          prevention: ['Drinking water and food hygiene, mass prophylaxis with vaccine in outbreaks'],
          dosing: {
            adult: {
              doxycycline: '300 mg PO single dose (adults) according to most protocols',
              azithromycin: '1 g PO single dose (alternative in pregnant women/children according to local protocol)'
            },
            pediatric: 'Pediatric doses weight dependent; Azithromycin pediatric dose according to local guideline'
          },
        },
        prognosis: { mortality: 'With treatment <1%, untreated 50%', prognostic_scores: [], factors: 'Age, comorbidity' },
        references: [
          { text: 'WHO – Cholera and acute diarrhoeal disease guidance', url: 'https://www.who.int/health-topics/diarrhoeal-diseases' },
          { text: 'CDC – Cholera', url: 'https://www.cdc.gov/cholera/index.html' }
        ]
      },
      {
        id: 'travelers_diarrhea',
        name: "Traveler's Diarrhea",
        pathogen: { type: 'Syndrome', name: '<i>ETEC</i> (most common), <i>Campylobacter, Salmonella, Shigella</i>, Viruses', gram: 'Variable', shape: '-' },
        epidemiology: {
          incidence: '20-60% of travelers (to developing countries)',
          risk_groups: ['Young adults', 'Immunosuppressed', 'PPI users'],
          seasonality: 'None',
          transmission: 'Fecal-oral (food, water)'
        },
        pathomechanism: {
          steps: [
            'Infection is most commonly caused by enterotoxin-producing E. coli (ETEC) or invasive bacteria (Campylobacter, Shigella).',
            'Pathogens trigger inflammation or fluid secretion in travelers encountering a microbiome different from local hygiene conditions.'
          ],
          virulence_factors: ['Variable']
        },
        clinical: {
          incubation: 'During travel or after return',
          onset: 'Acute',
          symptoms: [
            { name: 'Diarrhea', description: 'Watery diarrhea with abdominal cramps occurring during or after travel.', severity: 'moderate' },
            { name: 'Fever', description: 'Fever and bloody stool suggest an invasive pathogen.', severity: 'moderate' }
          ],
          physical_exam: ['Mild abdominal tenderness', 'Signs of dehydration'],
          complications: ['Dehydration', 'Post-infectious IBS', 'Reactive arthritis']
        },
        diagnostics: {
          laboratory: [{ test: '-', finding: '-', interpretation: 'Usually not necessary' }],
          microbiology: [{ test: 'Stool culture/PCR', finding: 'Multiplex panel', significance: 'Only in persistent/severe cases or immunosuppressed' }]
        },
        differential: [
          { disease: 'IBD flare', distinguishing: 'History, endoscopy' },
          { disease: 'Giardiasis', distinguishing: 'Prolonged, greasy stool' }
        ],
        therapy: {
          empirical: {
            outpatient: [
              { drug: 'Azithromycin', dose: '1000mg PO once or 500mg for 3 days', duration: '', note: 'Southeast Asia (Campy resistance) or dysentery' },
              { drug: 'Rifaximin', dose: '2x200mg PO', duration: '3 days', note: 'In non-invasive (afebrile) cases' },
              { drug: 'Ciprofloxacin', dose: '2x500mg PO', duration: '1-3 days', note: 'Other regions (but resistance is increasing)' }
            ]
          },
          targeted: '-',
          supportive: ['Fluid replacement', 'Loperamide (only if no fever/bloody stool!)'],
          prevention: ['"Boil it, cook it, peel it or forget it"', 'Hand washing', 'Rifaximin prophylaxis (only in high-risk cases)']
        },
        guidelines: {
          diagnosis: [
            'Suspicion: acute diarrhea after or during travel; mostly no microbiological examination needed in mild cases',
            'In severe, persistent or febrile cases stool culture/PCR multiplex panel recommended'
          ],
          treatment_indications: [
            'Mild case: only rehydration and symptomatic treatment',
            'Severe, febrile, dysenteric case or immunosuppressed patient: antibiotic treatment recommended'
          ],
          first_line: [
            'Non-invasive (afebrile) cases: Rifaximin 2x200 mg 3 days',
            'With dysentery or in Southeast Asia: Azithromycin 1 g single or 500 mg 3 days'
          ],
          supportive: ['ORS, loperamide only if no fever/bloody stool, electrolyte replacement'],
          prevention: ['Food and water safety during travel; prophylaxis only in exceptional cases'],
          dosing: {
            adult: {
              rifaximin: '200 mg PO 3 times daily for 3 days (non-invasive traveler\'s diarrhea)',
              azithromycin: '1 g PO single dose (alternative) or 500 mg PO daily for 3 days'
            },
            pediatric: 'Pediatric doses weight and age dependent; request local pediatric protocol'
          },
        },
        prognosis: { mortality: 'Very low', prognostic_scores: [], factors: 'Age, immune status' },
        references: [
          { text: 'CDC – Traveler\'s Health: Traveler\'s Diarrhea', url: 'https://wwwnc.cdc.gov/travel/yellowbook/2024/infectious-diseases-related-to-travel/traveler-s-diarrhea' },
          { text: 'WHO – Management of diarrhoea', url: 'https://www.who.int/news-room/fact-sheets/detail/diarrhoeal-disease' }
        ]
      },
      {
        id: 'dysentery_syndrome',
        name: 'Dysentery Syndrome',
        pathogen: { type: 'Syndrome', name: '<i>Shigella, EIEC, EHEC, Campylobacter, Entamoeba, Salmonella</i>', gram: 'Variable', shape: '-' },
        epidemiology: {
          incidence: 'Variable',
          risk_groups: ['Children', 'Elderly', 'Immunosuppressed'],
          transmission: 'Fecal-oral'
        },
        pathomechanism: {
          steps: [
            'Pathogens (Shigella, EIEC, EHEC, Campylobacter, Entamoeba) invade the colonic mucosa.',
            'Tissue invasion causes severe inflammation, ulceration, bleeding, and mucus production.'
          ],
          virulence_factors: ['Invasins', 'Cytotoxins']
        },
        clinical: {
          incubation: 'Variable',
          onset: 'Acute',
          symptoms: [
            { name: 'Bloody-mucoid Diarrhea', description: 'Frequent, small-volume, bloody-mucoid-purulent stools.', severity: 'severe' },
            { name: 'Tenesmus', description: 'Painful, ineffective urge to defecate.', severity: 'severe' }
          ],
          physical_exam: ['Lower abdominal tenderness', 'Fever', 'Toxic state'],
          complications: ['HUS (EHEC/Shigella)', 'Toxic megacolon', 'Perforation', 'Sepsis', 'Rectal prolapse']
        },
        diagnostics: {
          laboratory: [{ test: 'CBC', finding: 'Leukocytosis', interpretation: 'Inflammation' }],
          microbiology: [
            { test: 'Stool culture', finding: 'Pathogen search', significance: 'Mandatory!' },
            { test: 'Parasite exam', finding: 'E. histolytica', significance: 'If culture is negative' },
            { test: 'Shiga toxin', finding: 'Positive', significance: 'EHEC/Shigella' }
          ]
        },
        differential: [
          { disease: 'Inflammatory bowel disease (IBD)', distinguishing: 'Chronic history, endoscopy, biopsy' },
          { disease: 'Ischemic colitis', distinguishing: 'Older age, vascular risk factors, CT' }
        ],
        therapy: {
          empirical: {
            outpatient: [
              { drug: 'Azithromycin', dose: '1x500mg PO', duration: '3 days', note: 'First choice' },
              { drug: 'Ciprofloxacin', dose: '2x500mg PO', duration: '3-5 days', note: 'Alternative (resistance?)' }
            ]
          },
          targeted: 'Based on culture. Antibiotics contraindicated in EHEC! Amoeba: Metronidazole.',
          supportive: ['Fluid replacement', 'Antimotility agents (Loperamide) are CONTRAINDICATED!'],
          prevention: ['Hygiene', 'Isolation']
        },
        guidelines: {
          diagnosis: [
            'Suspicion: bloody-mucoid diarrhea, tenesmus; differentiation between EHEC, Shigella, Entamoeba, Campylobacter required',
            'Mandatory: stool culture, Shiga-toxin test and parasite exam depending on epidemic or clinical indication'
          ],
          treatment_indications: [
            'Antibiotics recommended in severe invasive infection, epidemic control and risk groups (infant, elderly, immunosuppressed)',
            'In EHEC or confirmed Shiga-toxin positive case AB generally contraindicated (increasing HUS risk)'
          ],
          first_line: [
            'Shigella: Azithromycin or Ceftriaxone; Campylobacter: Azithromycin; Salmonella invasive: Ceftriaxone or Ciprofloxacin (consider resistance)'
          ],
          supportive: ['ORS, continuous monitoring in severe cases; avoid antimotility agents in dysentery'],
          prevention: ['Hand hygiene, food hygiene; in outbreaks contact isolation and public health measures']
        },
        prognosis: { mortality: 'Variable, more severe in EHEC/S. dysenteriae type 1', prognostic_scores: [], factors: 'Age, pathogen type' },
        references: [
          { text: 'WHO Dysentery (Shigellosis) Guidelines', url: 'https://www.who.int/health-topics/shigellosis' },
          { text: 'CDC Shigella - Resources for Healthcare Professionals', url: 'https://www.cdc.gov/shigella/hcp/index.html' }
        ]
      }
    ]
  },
  viral_hepatitis: {
    name: 'Viral Hepatitis',
    icon: '🧬',
    color: '#eab308',
    tables: [
      {
        title: 'Differential Diagnosis of Viral Hepatitis',
        headers: ['Virus', 'Transmission', 'Incubation', 'Chronicity', 'Key Serology', 'Key Features'],
        rows: [
          ['HAV', 'Fecal-oral', '2-6 weeks', 'No', 'Anti-HAV IgM', 'Acute, outbreaks, travel-related'],
          ['HBV', 'Parenteral, sexual', '2-6 months', 'Yes (esp. perinatal)', 'HBsAg, Anti-HBc IgM', 'Chronic liver disease, HCC risk'],
          ['HCV', 'Parenteral', '2-26 weeks', 'Yes (>70%)', 'Anti-HCV, HCV RNA', 'Chronic, curable (DAAs), extrahepatic manifestations'],
          ['HDV', 'Parenteral (with HBV)', 'Variable', 'Yes (superinfection)', 'Anti-HDV (in HBsAg+ patient)', 'Worsens HBV, rapid progression to cirrhosis'],
          ['HEV', 'Fecal-oral (G1,2), Zoonotic (G3,4)', '2-10 weeks', 'Yes (immunosuppressed)', 'Anti-HEV IgM, HEV RNA', 'Fulminant in pregnancy, associated with pork']
        ]
      },
      {
        title: 'Interpretation of Hepatitis B Serologic Patterns',
        headers: ['HBsAg', 'Anti-HBs', 'Anti-HBc (Total)', 'Anti-HBc IgM', 'Interpretation'],
        rows: [
          ['-', '-', '-', '-', 'Susceptible (not infected, not immune)'],
          ['-', '+', '-', '-', 'Immune (due to vaccination)'],
          ['-', '+', '+', '-', 'Immune (due to natural infection)'],
          ['+', '-', '+', '+', 'Acutely infected'],
          ['+', '-', '+', '-', 'Chronically infected'],
          ['-', '-', '+', '-', 'Possible: 1. Resolved infection (low Anti-HBs); 2. False positive; 3. Occult HBV; 4. Window period']
        ]
      },
      {
        title: 'Meaning of Hepatitis Serological Markers',
        headers: ['Marker', 'Virus', 'Meaning'],
        rows: [
          ['Anti-HAV IgM', 'HAV', 'Acute infection'],
          ['Anti-HAV IgG', 'HAV', 'Immunity (vaccination or past infection)'],
          ['HBsAg', 'HBV', 'Presence of infection (acute or chronic)'],
          ['Anti-HBs', 'HBV', 'Immunity (vaccination or recovery)'],
          ['Anti-HBc IgM', 'HBV', 'Acute infection (also in window period)'],
          ['Anti-HBc (Total)', 'HBV', 'Past or current infection'],
          ['HBeAg', 'HBV', 'High replication, infectivity'],
          ['Anti-HBe', 'HBV', 'Lower replication (seroconversion)'],
          ['HBV DNA', 'HBV', 'Viral replication level'],
          ['Anti-HCV', 'HCV', 'Exposure (not necessarily active)'],
          ['HCV RNA', 'HCV', 'Active infection'],
          ['Anti-HDV', 'HDV', 'HDV infection (only with HBV)'],
          ['Anti-HEV IgM', 'HEV', 'Acute infection']
        ]
      }
    ],
    diseases: [
      {
        id: 'hav',
        name: 'Hepatitis A',
        pathogen: { type: 'Virus', name: '<i>Hepatitis A virus</i> (HAV)', gram: 'ssRNA, Picornaviridae', shape: 'icosahedral' },
        epidemiology: {
          incidence: 'High in endemic areas, sporadic/epidemic in developed countries',
          risk_groups: ['Travelers', 'MSM', 'Intravenous drug users', 'Homeless'],
          seasonality: 'None',
          transmission: 'Fecal-oral (contaminated water, food), sexual (oral-anal)'
        },
        pathomechanism: {
          steps: [
            'Oral Entry: The virus is absorbed from the gut and reaches the liver via the portal circulation.',
            'Hepatocyte Infection: The virus enters hepatocytes via the HAVCR-1 receptor, replicates in the cytoplasm, but does not cause direct cell death (non-cytopathic).',
            'Immune Response: Hepatocyte damage is caused by the host\'s own cellular immune response (CD8+ cytotoxic T-cells and NK cells) killing infected hepatocytes.',
            'Excretion: The virus is excreted into bile and stool, often before symptoms appear.'
          ],
          virulence_factors: ['Capsid stability (acid-resistant)', 'Membrane envelope in blood (eHAV) - immune evasion']
        },
        clinical: {
          incubation: '15-50 days (average 28 days)',
          onset: 'Sudden',
          symptoms: [
            { name: 'Prodrome', description: 'Flu-like symptoms (fever, headache, myalgia), anorexia, aversion to smoking/fatty foods.', severity: 'moderate' },
            { name: 'Icteric Phase', description: 'Dark urine (bilirubinuria), pale stool, followed by jaundice (skin, sclera). Fever often subsides by this time.', severity: 'moderate' },
            { name: 'Abdominal Symptoms', description: 'Dull right upper quadrant pain, hepatomegaly, nausea.', severity: 'mild' }
          ],
          physical_exam: [
            'Icterus (sclera, skin)',
            'Hepatomegaly, tender liver',
            'Splenomegaly (rare)',
            'Exanthema (rare)'
          ],
          complications: ['Fulminant hepatitis (<1%, more common in elderly)', 'Cholestatic hepatitis (prolonged)', 'Relapse (3-20%)', 'NO chronic carriage']
        },
        diagnostics: {
          laboratory: [
            { test: 'Liver enzymes', finding: 'ALT/AST >1000 U/L', interpretation: 'Acute hepatocellular necrosis' },
            { test: 'Bilirubin', finding: 'Elevated (direct and indirect)', interpretation: 'Icterus' },
            { test: 'ALP/GGT', finding: 'Moderately elevated', interpretation: 'Higher in cholestasis' }
          ],
          imaging: [
            { modality: 'Abdominal US', finding: 'Hepatomegaly, gallbladder wall thickening', significance: 'Non-specific' }
          ],
          microbiology: [
            { test: 'Anti-HAV IgM', finding: 'Positive', significance: 'Diagnosis of acute infection (remains + for 3-6 months)' },
            { test: 'Anti-HAV IgG', finding: 'Positive', significance: 'Immunity (vaccination or recovery)' },
            { test: 'HAV RNA (PCR)', finding: 'Positive', significance: 'Viremia (rarely needed)' }
          ]
        },
        differential: [
          { disease: 'Other viral hepatitis (HBV, HCV, HEV)', distinguishing: 'Serology (HBsAg, Anti-HCV, Anti-HEV)' },
          { disease: 'Toxic/Drug-induced hepatitis', distinguishing: 'History (acetaminophen, mushroom), toxicology' },
          { disease: 'Biliary obstruction (Choledocholithiasis)', distinguishing: 'Abdominal US (dilated ducts), ALP/GGT dominance, colic' },
          { disease: 'EBV/CMV mononucleosis', distinguishing: 'Sore throat, lymphadenopathy, monospot/serology' },
          { disease: 'Autoimmune hepatitis', distinguishing: 'Autoantibodies (ANA, ASMA), elevated IgG' }
        ],
        therapy: {
          empirical: {
            outpatient: [
              { drug: 'Supportive', dose: '-', duration: '-', note: 'Rest, adequate calories, no alcohol' }
            ],
            inpatient: [
              { drug: 'Supportive', dose: '-', duration: '-', note: 'In case of severe vomiting, dehydration, or coagulopathy' }
            ],
            icu: [
              { drug: 'Liver transplant', dose: 'Listing', duration: '', note: 'In case of fulminant liver failure' }
            ]
          },
          targeted: 'No specific antiviral agent.',
          supportive: ['Fluid replacement', 'Antiemetics', 'Avoid alcohol and hepatotoxic drugs'],
          prevention: ['Vaccination (inactivated, 2 doses)', 'Hygiene (hand washing)', 'Post-exposure prophylaxis (vaccine or IG within 2 weeks)']
        },
        guidelines: {
          diagnosis: [
            'Suspicion of acute hepatitis: liver enzymes (ALT/AST), bilirubin, ALP/GGT, INR',
            'Anti-HAV IgM positive confirms acute HAV infection; if suspicion of early window period repetition or HAV RNA (PCR) recommended',
            'In severe liver dysfunction coagulation parameters and transplant consultation'
          ],
          treatment_indications: [
            'Basically supportive treatment. Hospitalization in severe dehydration, coagulopathy or fulminant liver damage',
            'Evaluation for liver transplantation based on King\'s College criteria in fulminant case'
          ],
          post_exposure: [
            'After exposure within 2 weeks vaccine administration (if not previously vaccinated) or immunoglobulin (IG) in certain cases (elderly, immunosuppressed, chronic liver patients)'
          ],
          prevention: [
            'Vaccination: 2 doses (0 and 6–12 months), vaccination 2 weeks before travel optimal',
            'Hygiene, drinking water and food safety'
          ],
          special_populations: [
            'Pregnancy: HAV usually not more severe in pregnant women, but vaccination and post-exposure IG to be considered',
            'Immunodeficient patients: vaccination may be less effective, close monitoring recommended'
          ]
        },
        prognosis: {
          mortality: 'Low (<0.1%), but 1.8% over 50 years',
          prognostic_scores: ["King's College criteria (fulminant)"],
          factors: 'Age, underlying liver disease'
        },
        references: [
          'WHO. Hepatitis A fact sheet.',
          'CDC Yellow Book: Hepatitis A.'
        ],
        gallery: [
          {
            url: "data:image/svg+xml;utf8,<svg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 800 400' style='background-color:white'><defs><style>.txt{font-family:sans-serif;font-size:14px;}.axis{stroke:black;stroke-width:2;}.grid{stroke:%23eee;stroke-width:1;}</style></defs><path class='grid' d='M50,50 H750 M50,150 H750 M50,250 H750 M50,350 H750' /><line class='axis' x1='50' y1='350' x2='750' y2='350' /><line class='axis' x1='50' y1='350' x2='50' y2='50' /><text x='50' y='370' class='txt'>0</text><text x='200' y='370' class='txt'>1 mo</text><text x='350' y='370' class='txt'>3 mo</text><text x='500' y='370' class='txt'>6 mo</text><text x='650' y='370' class='txt'>1 yr</text><text x='350' y='390' class='txt' text-anchor='middle'>Time after exposure</text><text x='20' y='200' class='txt' transform='rotate(-90 20,200)' text-anchor='middle'>Titer</text><path d='M50,350 Q150,50 250,50 Q350,50 450,350' fill='none' stroke='purple' stroke-width='3' /><text x='200' y='40' class='txt' fill='purple'>Anti-HAV IgM</text><path d='M150,350 Q250,100 350,100 L750,100' fill='none' stroke='green' stroke-width='3' /><text x='600' y='90' class='txt' fill='green'>Anti-HAV IgG</text><path d='M50,350 Q100,200 150,200 Q200,200 220,350' fill='none' stroke='red' stroke-width='3' stroke-dasharray='5,5' /><text x='80' y='190' class='txt' fill='red'>Virus (stool)</text><path d='M100,350 Q180,150 220,150 Q260,150 300,350' fill='none' stroke='orange' stroke-width='2' /><text x='180' y='140' class='txt' fill='orange'>ALT (Symptoms)</text></svg>",
            caption: 'Serological course of Hepatitis A',
            type: 'Diagram'
          }
        ]
      },
      {
        id: 'hbv',
        name: 'Hepatitis B',
        pathogen: { type: 'Virus', name: '<i>Hepatitis B virus</i> (HBV)', gram: 'dsDNA (RT), Hepadnaviridae', shape: 'spherical (Dane particle)' },
        epidemiology: {
          incidence: '290 million chronic carriers worldwide',
          risk_groups: ['IV drug users', 'Sexual partners', 'Healthcare workers', 'Dialysis patients', 'Perinatal (mother-to-child)'],
          seasonality: 'None',
          transmission: 'Parenteral (blood), sexual, perinatal'
        },
        pathomechanism: {
          steps: [
            'Entry and Replication: The virus enters hepatocytes via the NTCP receptor. It forms cccDNA (covalently closed circular DNA) in the nucleus, which is the basis for persistence.',
            'Immune Pathogenesis: The virus itself is not cytopathic. Liver damage is caused by the cytotoxic T-cell immune response against infected cells.',
            'Chronicity: If the immune response is insufficient (e.g., in neonates), the virus persists. Viral DNA can integrate into the host genome, increasing the risk of hepatocellular carcinoma (HCC).'
          ],
          virulence_factors: ['HBsAg (decoy)', 'HBeAg (immunotolerance)', 'X protein (transactivator)']
        },
        clinical: {
          incubation: '45-160 days (average 90 days)',
          onset: 'Slow',
          symptoms: [
            { name: 'Acute Phase', description: 'Often asymptomatic. If symptomatic: serum sickness-like prodrome (rash, joint pain), then jaundice, fatigue, RUQ pain.', severity: 'moderate' },
            { name: 'Chronic Phase', description: 'Mostly asymptomatic ("silent killer"). In late stages, signs of liver cirrhosis (ascites, variceal bleeding, encephalopathy) dominate.', severity: 'mild' },
            { name: 'Extrahepatic Symptoms', description: 'Polyarteritis nodosa, glomerulonephritis.', severity: 'moderate' }
          ],
          physical_exam: [
            'Hepatomegaly',
            'Splenomegaly',
            'Spider naevi, palmar erythema (chronic/cirrhosis)',
            'Ascites, caput medusae (decompensated cirrhosis)'
          ],
          complications: ['Chronic hepatitis (90% in infants, <5% in adults)', 'Cirrhosis', 'Hepatocellular carcinoma (HCC)', 'Polyarteritis nodosa', 'Glomerulonephritis']
        },
        diagnostics: {
          laboratory: [
            { test: 'ALT/AST', finding: 'Elevated', interpretation: 'Activity of inflammation' }
          ],
          microbiology: [
            { test: 'HBsAg', finding: 'Positive', significance: 'Presence of infection (acute or chronic)' },
            { test: 'Anti-HBs', finding: 'Positive', significance: 'Immunity (vaccination or recovery)' },
            { test: 'Anti-HBc IgM', finding: 'Positive', significance: 'Acute infection (important in window period!)' },
            { test: 'Anti-HBc IgG', finding: 'Positive', significance: 'Past or chronic infection' },
            { test: 'HBeAg', finding: 'Positive', significance: 'High replication and infectivity' },
            { test: 'HBV DNA', finding: 'Positive', significance: 'Level of viral replication (therapy monitoring)' }
          ]
        },
        differential: [
          { disease: 'Other viral hepatitis (HAV, HCV, HDV)', distinguishing: 'Serology (Anti-HAV IgM, Anti-HCV, Anti-HDV)' },
          { disease: 'Autoimmune hepatitis', distinguishing: 'Autoantibodies (ANA, ASMA, LKM-1), hypergammaglobulinemia' },
          { disease: 'Alcoholic liver disease', distinguishing: 'History, AST > ALT (2:1 ratio), elevated GGT' },
          { disease: 'Drug-induced liver injury (DILI)', distinguishing: 'Medication history, improvement after withdrawal' },
          { disease: 'Wilson\'s disease', distinguishing: 'Young age, low ceruloplasmin, Kayser-Fleischer ring' }
        ],
        therapy: {
          guidelines: ['EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection'],
          empirical: {
            outpatient: [
              { drug: 'Entecavir', dose: '0.5 mg PO 1x/day', duration: 'Long-term', note: 'Nucleoside analogue. 1 mg in case of lamivudine resistance.' },
              { drug: 'Tenofovir disoproxil (TDF)', dose: '300 mg PO 1x/day', duration: 'Long-term', note: 'Nucleotide analogue. Renal function and bone density monitoring required.' },
              { drug: 'Tenofovir alafenamide (TAF)', dose: '25 mg PO 1x/day', duration: 'Long-term', note: 'Preferred if risk of bone/kidney disease.' }
            ],
            inpatient: [
              { drug: 'Tenofovir (TDF/TAF) or Entecavir', dose: 'Standard', duration: '', note: 'Start immediately in severe acute hepatitis or acute liver failure.' }
            ]
          },
          targeted: 'Chronic HBV: Lifelong NA (Entecavir, TDF, TAF) to suppress viral replication. Finite treatment: Peg-IFN alpha (48 weeks) in selected patients.',
          supportive: ['HCC screening (US every 6 months)', 'Vaccination against HAV', 'Screening of family members'],
          prevention: ['Vaccination (recombinant HBsAg, 0-1-6 months)', 'Screening in pregnancy', 'HBIG + vaccine for newborns (≤12 hours; continue vaccination series)']
        },
        guidelines: {
          definitions: [
            'Acute HBV: HBsAg positive and Anti-HBc IgM positive, with or without symptoms',
            'Chronic HBV: HBsAg positive >6 months',
            'Treatment indication: Chronic hepatitis (ALT elevated + HBV DNA >2000 IU/ml + fibrosis) OR Cirrhosis (at any HBV DNA level)'
          ],
          diagnosis: [
            'Initial examination: HBsAg, Anti-HBs, Anti-HBc (IgM/IgG), HBeAg/Anti-HBe, HBV DNA (quantitative)',
            'Fibrosis assessment: FibroScan or serum markers (FIB-4)'
          ],
          treatment_indications: [
            'All cirrhotic patients must be treated',
            'HBeAg positive or negative chronic hepatitis (ALT > ULN, DNA > 2000 IU/ml, F2+ fibrosis)',
            'Before immunosuppression in HBsAg+ patients (prophylaxis)'
          ],
          first_line: [
            'Entecavir, TDF, TAF (high resistance barrier NAs)',
            'Peg-IFN alpha (48 weeks) - alternative in mild/moderate fibrosis'
          ],
          special_populations: [
            'Pregnancy: TDF from 24-28th week if HBV DNA >200,000 IU/ml',
            'Renal failure: TAF or Entecavir (dose adjustment)',
            'HDV coinfection: Peg-IFN or Bulevirtide'
          ],
          monitoring: [
            'Under NA therapy: ALT and HBV DNA every 3-6 months',
            'HCC screening with ultrasound ± AFP every 6 months in cirrhotic patients'
          ]
        },
        prognosis: {
          mortality: 'Acute: <1%; Chronic: significant due to cirrhosis/HCC',
          prognostic_scores: ['PAGE-B (HCC risk)'],
          factors: 'HBeAg status, viral load, genotype, coinfections'
        },
        references: [
          'EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-398. doi:10.1016/j.jhep.2017.03.021',
          'WHO Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. 2015.'
        ]
      },
      {
        id: 'hcv',
        name: 'Hepatitis C',
        pathogen: { type: 'Virus', name: '<i>Hepatitis C virus</i> (HCV)', gram: 'ssRNA, Flaviviridae', shape: 'spherical, enveloped' },
        epidemiology: {
          incidence: '71 million chronic patients worldwide',
          risk_groups: ['IV drug users', 'Transfusion (before 1992)', 'Tattoo/piercing', 'Healthcare workers (needlestick)'],
          seasonality: 'None',
          transmission: 'Parenteral (blood), sexual (rare, higher in MSM), perinatal'
        },
        pathomechanism: {
          steps: [
            'Replication: The virus replicates in the cytoplasm of hepatocytes (no nuclear phase, hence curable).',
            'Immune Evasion: The viral RNA polymerase is error-prone, leading to constant mutation (quasispecies) and evasion of immune recognition.',
            'Fibrosis: Chronic inflammation activates stellate cells, which produce collagen, leading to liver fibrosis and eventually cirrhosis.'
          ],
          virulence_factors: ['NS3/4A protease', 'NS5A/B polymerase', 'Lipid metabolism modulation']
        },
        clinical: {
          incubation: '14-180 days',
          onset: 'Slow/Asymptomatic',
          symptoms: [
            { name: 'Acute Phase', description: 'Rarely diagnosed (80% asymptomatic). Mild fatigue, anorexia may occur.', severity: 'mild' },
            { name: 'Chronic Phase', description: 'Can be asymptomatic for decades. The leading symptom is chronic fatigue. Often only complications of cirrhosis or lab findings draw attention.', severity: 'moderate' },
            { name: 'Extrahepatic Symptoms', description: 'Cryoglobulinemia (vasculitis), porphyria cutanea tarda, lichen planus, diabetes.', severity: 'moderate' }
          ],
          physical_exam: [
            'Often negative',
            'Signs of cirrhosis in late stage'
          ],
          complications: ['Chronic hepatitis (70-80%!)', 'Cirrhosis (20-30% in 20 years)', 'HCC', 'Extrahepatic: Cryoglobulinemia, Porphyria cutanea tarda, Lichen planus, Diabetes']
        },
        diagnostics: {
          laboratory: [
            { test: 'ALT', finding: 'Fluctuatingly elevated', interpretation: 'Chronic inflammation' }
          ],
          microbiology: [
            { test: 'Anti-HCV', finding: 'Positive', significance: 'Exposure (not necessarily active infection)' },
            { test: 'HCV RNA', finding: 'Positive', significance: 'Active infection (confirmation needed!)' },
            { test: 'Genotyping', finding: '1-6', significance: 'Choice of therapy (though pangenotypic drugs dominate)' }
          ]
        },
        differential: [
          { disease: 'Hepatitis B', distinguishing: 'HBsAg positive' },
          { disease: 'Alcoholic liver disease', distinguishing: 'History, AST > ALT, macrocytosis' },
          { disease: 'Non-alcoholic fatty liver disease (NAFLD/NASH)', distinguishing: 'Metabolic syndrome, US (steatosis), biopsy' },
          { disease: 'Autoimmune hepatitis', distinguishing: 'Autoantibodies, histology (plasma cell infiltration)' },
          { disease: 'Hemochromatosis', distinguishing: 'High ferritin, transferrin saturation, HFE gene mutation' }
        ],
        therapy: {
          guidelines: ['EASL Recommendations on Treatment of Hepatitis C 2020'],
          empirical: {
            outpatient: [
              { drug: 'Glecaprevir / Pibrentasvir (Maviret)', dose: '3 tabs (300/120mg) PO 1x', duration: '8 weeks', note: 'Pangenotypic. 8 weeks in both non-cirrhotic and compensated cirrhotic patients.' },
              { drug: 'Sofosbuvir / Velpatasvir (Epclusa)', dose: '1 tab (400/100mg) PO 1x', duration: '12 weeks', note: 'Pangenotypic. Can be given in decompensated cirrhosis (with RBV).' }
            ]
          },
          targeted: 'Pangenotypic DAA treatment for all patients (Simplified treatment). Genotyping not necessarily required to start treatment (except in cirrhosis/previous treatment failure).',
          supportive: ['Check drug interactions (www.hep-druginteractions.org)', 'No alcohol'],
          prevention: ['No vaccine', 'Screening of blood products', 'Harm reduction (needle exchange)', 'Safe sex']
        },
        guidelines: {
          diagnosis: [
            'Screening: Anti-HCV serology (ELISA) in all risk groups and blood donation',
            'HCV RNA positive = Active infection -> Treatment'
          ],
          treatment_indications: [
            'All chronic HCV infected should be treated, except patients with short life expectancy or pregnancy',
            'Special priority: cirrhosis, extrahepatic manifestations, transplant candidates'
          ],
          first_line: [
            'Glecaprevir/Pibrentasvir (8 weeks)',
            'Sofosbuvir/Velpatasvir (12 weeks)'
          ],
          monitoring: [
            'SVR12 (Sustained Virologic Response): HCV RNA negative 12 weeks after treatment = Cure',
            'In case of cirrhosis HCC screening continues even after SVR!'
          ],
          special_populations: [
            'Decompensated cirrhosis: Protease inhibitors (Glecaprevir, Grazoprevir) CONTRAINDICATED! Sof/Vel + Ribavirin can be given.'
          ]
        },
        prognosis: {
          mortality: 'Excellent with treatment (SVR = cure), worse in cirrhosis',
          factors: 'Fibrosis stage, coinfection (HIV/HBV), alcohol'
        },
        references: [
          'EASL Recommendations on Treatment of Hepatitis C (2020 update).',
          'WHO. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection.'
        ],
        gallery: [
          {
            url: "data:image/svg+xml;utf8,<svg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 800 400' style='background-color:white'><defs><style>.txt{font-family:sans-serif;font-size:14px;}.axis{stroke:black;stroke-width:2;}.grid{stroke:%23eee;stroke-width:1;}</style></defs><path class='grid' d='M50,50 H750 M50,150 H750 M50,250 H750 M50,350 H750' /><line class='axis' x1='50' y1='350' x2='750' y2='350' /><line class='axis' x1='50' y1='350' x2='50' y2='50' /><text x='50' y='370' class='txt'>0</text><text x='150' y='370' class='txt'>2 mo</text><text x='250' y='370' class='txt'>6 mo</text><text x='450' y='370' class='txt'>1 yr</text><text x='650' y='370' class='txt'>Years...</text><text x='350' y='390' class='txt' text-anchor='middle'>Time after exposure</text><text x='20' y='200' class='txt' transform='rotate(-90 20,200)' text-anchor='middle'>Titer</text><path d='M50,350 Q80,50 150,50 L750,50' fill='none' stroke='red' stroke-width='3' /><text x='600' y='40' class='txt' fill='red'>HCV RNA</text><path d='M100,350 Q200,100 300,100 L750,100' fill='none' stroke='blue' stroke-width='3' /><text x='600' y='90' class='txt' fill='blue'>Anti-HCV</text><path d='M100,350 Q150,150 200,250 T300,200 T400,250 T500,200 T600,250 T700,200' fill='none' stroke='orange' stroke-width='2' /><text x='600' y='190' class='txt' fill='orange'>ALT (Fluctuating)</text></svg>",
            caption: 'Serological course of Chronic Hepatitis C',
            type: 'Diagram'
          }
        ]
      },
      {
        id: 'hdv',
        name: 'Hepatitis D',
        pathogen: { type: 'Virus', name: '<i>Hepatitis D virus</i> (HDV)', gram: 'ssRNA (defective)', shape: 'enveloped in HBsAg' },
        epidemiology: {
          incidence: '5% of HBV infected (approx. 15-20 million)',
          seasonality: 'None',
          risk_groups: ['HBV infected', 'IV drug users', 'Sexual partners', 'Healthcare workers'],
          transmission: 'Parenteral, sexual (like HBV). Only infects in the presence of HBV!'
        },
        pathomechanism: {
          steps: [
            'Defective Virus: Requires Hepatitis B virus surface antigen (HBsAg) for replication and packaging of infectious particles.',
            'Coinfection: Simultaneous infection with HBV and HDV. Usually causes severe acute hepatitis, but chronicity is rare (<5%).',
            'Superinfection: Chronic HBV carrier infected with HDV. This is the most severe form, often leading to fulminant course or rapidly progressive cirrhosis.'
          ],
          virulence_factors: ['Delta antigen (HDAg)']
        },
        clinical: {
          incubation: '30-60 days',
          onset: 'Sudden',
          symptoms: [
            { name: 'Exacerbation', description: 'Sudden deterioration of a known HBV patient\'s condition (acute flare).', severity: 'severe' },
            { name: 'Decompensation', description: 'Rapidly developing liver failure, jaundice, coagulopathy.', severity: 'severe' }
          ],
          complications: ['Fulminant hepatitis', 'Rapid progression to cirrhosis (most aggressive viral hepatitis)']
        },
        diagnostics: {
          laboratory: [
            { test: 'ALT/AST', finding: 'elevated', interpretation: 'Acute flare' }
          ],
          microbiology: [
            { test: 'Anti-HDV', finding: 'Positive', significance: 'Screening in all HBV patients' },
            { test: 'HDV RNA', finding: 'Positive', significance: 'Active replication' }
          ]
        },
        differential: [
          { disease: 'HBV coinfection', distinguishing: 'HDV RNA positive, Anti-HDV positive' },
          { disease: 'Acute HBV flare', distinguishing: 'HDV RNA negative, Anti-HDV negative' }
        ],
        therapy: {
          guidelines: ['EASL Clinical Practice Guidelines on hepatitis delta virus 2023'],
          empirical: {
            outpatient: [
              { drug: 'Bulevirtide', dose: '2 mg SC daily', duration: 'Long-term', note: 'Entry inhibitor. Monotherapy or in combination with Peg-IFN. (Conditional approval)' },
              { drug: 'Peg-IFN alfa', dose: '180 mcg SC weekly', duration: '48 weeks', note: 'Alternative, but low sustained response rate.' }
            ]
          },
          targeted: 'Bulevirtide (long-term maintenance) or Peg-IFN (48 weeks). Nucleoside analogues (against HBV) should be continued but do not directly affect HDV.',
          prevention: ['HBV vaccination also protects against HDV (as it needs HBsAg)']
        },
        guidelines: {
          screening: ['All HBsAg positive patients should be screened once for anti-HDV'],
          treatment: [
            'Bulevirtide 2mg SC daily: In compensated liver disease and HDV RNA positivity. Treatment as long as clinical benefit exists (years).',
            'Peg-IFN alfa: 48-week course can be attempted (approx. 25% sustained response).'
          ],
          monitoring: ['HDV RNA, ALT, HBsAg']
        },
        prognosis: {
          mortality: 'High, rapid cirrhosis progression',
          factors: 'Superinfection has worse prognosis'
        },
        references: [
          'EASL Clinical Practice Guidelines on hepatitis delta virus (2023).',
          'WHO. Hepatitis D resources and technical brief.'
        ],
        gallery: [
          {
            url: "data:image/svg+xml;utf8,<svg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 800 400' style='background-color:white'><defs><style>.txt{font-family:sans-serif;font-size:14px;}.axis{stroke:black;stroke-width:2;}.grid{stroke:%23eee;stroke-width:1;}</style></defs><path class='grid' d='M50,50 H750 M50,150 H750 M50,250 H750 M50,350 H750' /><line class='axis' x1='50' y1='350' x2='750' y2='350' /><line class='axis' x1='50' y1='350' x2='50' y2='50' /><text x='50' y='370' class='txt'>Chronic HBV</text><text x='300' y='370' class='txt'>HDV Infection</text><text x='600' y='370' class='txt'>Time</text><text x='20' y='200' class='txt' transform='rotate(-90 20,200)' text-anchor='middle'>Titer</text><path d='M50,100 L750,100' fill='none' stroke='red' stroke-width='3' /><text x='100' y='90' class='txt' fill='red'>HBsAg (Present)</text><path d='M250,350 Q300,50 400,50 L750,50' fill='none' stroke='purple' stroke-width='3' /><text x='450' y='40' class='txt' fill='purple'>HDV RNA / Anti-HDV IgM</text><path d='M300,350 Q400,120 500,120 L750,120' fill='none' stroke='blue' stroke-width='3' /><text x='600' y='110' class='txt' fill='blue'>Anti-HDV Total</text><path d='M50,300 L250,300 Q300,150 350,250 T450,200 T550,250 T650,200' fill='none' stroke='orange' stroke-width='2' /><text x='500' y='190' class='txt' fill='orange'>ALT (Flare-up)</text></svg>",
            caption: 'Serology of Hepatitis D superinfection',
            type: 'Diagram'
          }
        ]
      },
      {
        id: 'hev',
        name: 'Hepatitis E',
        pathogen: { type: 'Virus', name: '<i>Hepatitis E virus</i> (HEV)', gram: 'ssRNA, Hepeviridae', shape: 'icosahedral' },
        epidemiology: {
          incidence: 'Developing countries (water), Developed (pork/wild boar)',
          risk_groups: ['Pregnant women (severe course)', 'Immunosuppressed (chronic)', 'Liver patients', 'Pig farmers'],
          seasonality: 'Rainy season (tropics)',
          transmission: 'Fecal-oral (water - Genotype 1,2), Zoonosis (raw pork/game meat - Genotype 3,4)'
        },
        pathomechanism: {
          steps: [
            'Entry: Fecal-oral (contaminated water - Genotype 1,2) or zoonosis (raw meat - Genotype 3,4).',
            'Pregnancy: In pregnant women (especially 3rd trimester), the virus can cause fulminant liver failure, likely due to hormonal and immunological changes (20% mortality).',
            'Chronicity: In immunosuppressed patients (e.g., transplant recipients), the virus is not eliminated, causing chronic hepatitis and fibrosis.'
          ],
          virulence_factors: ['ORF3 protein (release)', 'Capsid protein']
        },
        clinical: {
          incubation: '15-60 days (average 40)',
          onset: 'Sudden',
          symptoms: [
            { name: 'Acute Hepatitis', description: 'Similar to HAV (fever, jaundice, vomiting).', severity: 'moderate' },
            { name: 'Neurological Symptoms', description: 'More frequently associated with neurological complications (Guillain-Barré syndrome, neuralgic amyotrophy).', severity: 'severe' },
            { name: 'In Pregnancy', description: 'Signs of severe, life-threatening liver failure.', severity: 'severe' }
          ],
          physical_exam: ['Icterus', 'Hepatomegaly'],
          complications: ['Fulminant hepatitis in pregnant women (20% mortality! - G1,2)', 'Chronic hepatitis in immunosuppressed (G3)', 'Neurological symptoms (Guillain-Barré, Neuralgic amyotrophy)']
        },
        diagnostics: {
          laboratory: [
            { test: 'Liver enzymes', finding: 'ALT/AST elevated', interpretation: 'Hepatitis' }
          ],
          imaging: [
            { modality: 'Abdominal US', finding: 'Hepatomegaly', significance: 'Non-specific' }
          ],
          microbiology: [
            { test: 'Anti-HEV IgM', finding: 'Positive', significance: 'Acute infection' },
            { test: 'HEV RNA', finding: 'Positive', significance: 'Confirmation, chronic case' }
          ]
        },
        differential: [
          { disease: 'Hepatitis A', distinguishing: 'Serology (Anti-HAV IgM)' },
          { disease: 'Drug-induced liver injury (DILI)', distinguishing: 'History (e.g., antibiotics, NSAIDs)' },
          { disease: 'Ischemic hepatitis', distinguishing: 'History of shock/hypotension, extreme LDH elevation' },
          { disease: 'Wilson\'s disease (in fulminant cases)', distinguishing: 'Hemolysis, low ALP, high urine copper' }
        ],
        therapy: {
          guidelines: ['EASL Clinical Practice Guidelines on hepatitis E virus infection'],
          empirical: {
            outpatient: [
              { drug: 'Supportive', dose: '-', duration: '-', note: 'In immunocompetent acute infection (self-limiting).' }
            ],
            inpatient: [
              { drug: 'Ribavirin', dose: '600-800 mg PO', duration: '12 weeks', note: 'Chronic HEV (immunosuppressed) or severe acute cases.' }
            ]
          },
          targeted: 'Chronic HEV (immunosuppressed): 1. Reduce immunosuppression (if possible). 2. Ribavirin for 12 weeks. If unsuccessful: Ribavirin for 24 weeks or Peg-IFN.',
          supportive: ['Fluid replacement', 'Close monitoring in pregnant women (risk of fulminant course!)'],
          prevention: ['Food safety (thorough cooking of pork/game meat)']
        },
        guidelines: {
          diagnosis: ['Anti-HEV IgM and IgG', 'HEV RNA (blood and stool) - mandatory in suspicion of chronic infection'],
          treatment_indications: [
            'Acute: usually does not require treatment (except liver failure)',
            'Chronic (>3 months HEV RNA+): Immunosuppressed patients (transplant, HIV). Treatment: Ribavirin.'
          ]
        },
        prognosis: {
          mortality: 'Generally low; in pregnant women (genotype 1–2) mortality up to 20%',
          prognostic_scores: ['None'],
          factors: 'Pregnancy, immunosuppression'
        },
        references: [
          'EASL Clinical Practice Guidelines on hepatitis E virus infection.',
          'WHO. Hepatitis E fact sheet.'
        ],
        gallery: [
          {
            url: "data:image/svg+xml;utf8,<svg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 800 400' style='background-color:white'><defs><style>.txt{font-family:sans-serif;font-size:14px;}.axis{stroke:black;stroke-width:2;}.grid{stroke:%23eee;stroke-width:1;}</style></defs><path class='grid' d='M50,50 H750 M50,150 H750 M50,250 H750 M50,350 H750' /><line class='axis' x1='50' y1='350' x2='750' y2='350' /><line class='axis' x1='50' y1='350' x2='50' y2='50' /><text x='50' y='370' class='txt'>0</text><text x='200' y='370' class='txt'>1 mo</text><text x='350' y='370' class='txt'>3 mo</text><text x='500' y='370' class='txt'>6 mo</text><text x='650' y='370' class='txt'>1 yr</text><text x='350' y='390' class='txt' text-anchor='middle'>Time after exposure</text><text x='20' y='200' class='txt' transform='rotate(-90 20,200)' text-anchor='middle'>Titer</text><path d='M50,350 Q150,50 250,50 Q350,50 450,350' fill='none' stroke='purple' stroke-width='3' /><text x='200' y='40' class='txt' fill='purple'>Anti-HEV IgM</text><path d='M150,350 Q250,100 350,100 L750,100' fill='none' stroke='green' stroke-width='3' /><text x='600' y='90' class='txt' fill='green'>Anti-HEV IgG</text><path d='M50,350 Q100,200 150,200 Q200,200 220,350' fill='none' stroke='red' stroke-width='3' stroke-dasharray='5,5' /><text x='80' y='190' class='txt' fill='red'>HEV RNA (stool)</text><path d='M100,350 Q180,150 220,150 Q260,150 300,350' fill='none' stroke='orange' stroke-width='2' /><text x='180' y='140' class='txt' fill='orange'>ALT</text></svg>",
            caption: 'Serological course of Hepatitis E',
            type: 'Diagram'
          }
        ]
      },
      {
        id: 'hgv',
        name: 'Hepatitis G virus / Human Pegivirus 1 (HPgV-1 / GBV-C)',
        pathogen: { type: 'Virus', name: '<i>Human Pegivirus 1</i> (HPgV-1, formerly GBV-C / HGV)', gram: 'ssRNA (+), Flaviviridae (genus Pegivirus)', shape: 'spherical, enveloped' },
        epidemiology: {
          incidence: 'Worldwide distribution; 1–5% of healthy blood donors are persistently viremic. 20–50% of the general population have Anti-E2 antibodies.',
          risk_groups: ['People who inject drugs (PWID)', 'Hemodialysis patients', 'Multiple blood product recipients', 'HIV and HCV co-infected individuals', 'High-risk sexual behavior'],
          seasonality: 'None',
          transmission: 'Parenteral (blood, needle stick, blood products), sexual contact, vertical (mother-to-child)'
        },
        pathomechanism: {
          steps: [
            'Lymphotropic virus: Replicates primarily in T and B lymphocytes and peripheral blood mononuclear cells (PBMCs). NOT hepatotropic!',
            'Does not cause hepatocyte injury, cytopathic effects, or histological liver inflammation.',
            'In HIV-1 co-infection, exerts favorable immunomodulatory effects: downregulates HIV co-receptors (CD4, CXCR4, CCR5) and upregulates inhibitory chemokines (SDF-1, RANTES, MIP-1α/β).',
            'Reduces T-cell hyperactivation and apoptosis, thereby slowing CD4+ decline and delaying HIV/AIDS disease progression.'
          ],
          virulence_factors: ['E2 envelope glycoprotein (cell entry, immunomodulation)', 'NS5A non-structural protein']
        },
        clinical: {
          incubation: '14–60 days, clinically irrelevant',
          onset: 'Asymptomatic',
          symptoms: [
            { name: 'Asymptomatic infection', description: 'Does NOT independently cause acute or chronic hepatitis, liver cirrhosis, or liver failure. "Hepatitis G" is a historical misnomer.', severity: 'mild' }
          ],
          physical_exam: ['Physical examination completely normal (no jaundice, no hepatomegaly)'],
          complications: ['No hepatic complications.', 'In HIV-1 co-infection, persistent HPgV-1 viremia slows HIV disease progression and improves survival (protective effect).']
        },
        diagnostics: {
          laboratory: [{ test: 'Liver enzymes (ALT, AST), Bilirubin, ALP, GGT', finding: 'Completely within normal reference limits', interpretation: 'No hepatocellular damage' }],
          imaging: [{ modality: 'Abdominal ultrasound', finding: 'Normal liver parenchyma and biliary tract', significance: 'Excludes other pathology' }],
          microbiology: [
            { test: 'HPgV-1 RT-PCR', finding: 'RNA detection', significance: 'Research/specialized setting; confirms active viremia' },
            { test: 'Anti-E2 antibody', finding: 'Positive', significance: 'Indicates clearance of viremia and past infection' }
          ]
        },
        differential: [
          { disease: 'True hepatotropic viruses (HBV, HCV, HAV, HEV, HDV)', distinguishing: 'Serology and PCR assays (HBsAg, Anti-HCV, HCV-RNA, etc.)' },
          { disease: 'Non-infectious liver diseases (DILI, NAFLD/NASH, Autoimmune hepatitis)', distinguishing: 'Diagnosis of exclusion, autoantibodies, toxicology' }
        ],
        therapy: {
          empirical: {},
          targeted: 'Does NOT require specific antiviral therapy.',
          supportive: ['No medical intervention required.'],
          prevention: ['Routine blood donor screening for HPgV-1 is not recommended. Standard infection control measures.']
        },
        prognosis: {
          mortality: 'Non-pathogenic to the liver (zero liver mortality).',
          prognostic_scores: [],
          factors: 'In HIV co-infection, HPgV-1 persistence is a favorable prognostic factor.'
        },
        references: [
          'Stapleton JT, et al. HPgV-1 (GBV-C) infection and pathogenesis. Nat Rev Microbiol.',
          'EASL & CDC Clinical Guidelines on Viral Hepatitis misnomers and Anelloviridae/Pegivirus.'
        ]
      },
      {
        id: 'ttv',
        name: 'Torque teno virus (TTV)',
        pathogen: { type: 'Virus', name: '<i>Torque teno virus</i> (TTV)', gram: 'ssDNA (-/+), Anelloviridae (genus Alphatorquevirus)', shape: 'small (28-32 nm), non-enveloped, icosahedral' },
        epidemiology: {
          incidence: 'Ubiquitous: present in >70–90% of healthy population as persistent viremia. Fundamental component of the human commensal virome.',
          risk_groups: ['General population', 'Solid organ transplant recipients (liver, kidney, heart, lung)', 'Immunosuppressed patients'],
          seasonality: 'None',
          transmission: 'Respiratory droplets, fecal-oral, parenteral, sexual, vertical, and breast milk'
        },
        pathomechanism: {
          steps: [
            'Systemic replication in bone marrow, PBMCs, T/B lymphocytes, liver, and lung tissues.',
            'Non-cytopathic: Does not cause hepatocyte necrosis or histological inflammation.',
            'Immune equilibrium: Plasma TTV DNA load inversely mirrors cellular immunocompetence of the host (T-cell function).',
            'Biomarker in organ transplantation: High TTV load indicates over-immunosuppression (risk of opportunistic infections like CMV, BKV, fungal infections); low TTV load indicates under-immunosuppression (risk of allograft rejection).'
          ],
          virulence_factors: ['ORF1 capsid protein (high genetic variability, immune evasion)']
        },
        clinical: {
          incubation: 'Not applicable (life-long commensal persistence)',
          onset: 'Asymptomatic',
          symptoms: [
            { name: 'Commensal state', description: 'Does not cause acute or chronic hepatitis or systemic illness.', severity: 'mild' }
          ],
          physical_exam: ['Unremarkable'],
          complications: ['No liver pathology. Quantitative plasma TTV DNA viral load serves as a valuable biomarker to tailor immunosuppressive therapy in organ transplant recipients.']
        },
        diagnostics: {
          laboratory: [{ test: 'Liver function panel (ALT, AST, Bilirubin)', finding: 'Normal', interpretation: 'No liver injury' }],
          imaging: [{ modality: 'Ultrasound', finding: 'Normal', significance: '-' }],
          microbiology: [
            { test: 'Quantitative Real-Time PCR (TTV DNA copies)', finding: 'DNA detection (copies/mL)', significance: 'Surrogate biomarker to monitor and guide immunosuppressive load in transplant recipients' }
          ]
        },
        differential: [
          { disease: 'Clinical hepatitis syndromes (HAV-HEV, EBV, CMV)', distinguishing: 'Serology, expanded PCR panel' }
        ],
        therapy: {
          empirical: {},
          targeted: 'Does NOT require antiviral therapy.',
          supportive: ['Dose adjustment of immunosuppressive drugs in transplant recipients based on TTV DNA levels (protocol-guided).'],
          prevention: ['Not feasible or required due to ubiquitous prevalence.']
        },
        prognosis: {
          mortality: 'Physiological virome component (zero mortality).',
          prognostic_scores: [],
          factors: 'TTV DNA load in transplant recipients correlates with infection and rejection risks.'
        }
      },
      {
        id: 'senv',
        name: 'SEN virus (SENV-D / SENV-H)',
        pathogen: { type: 'Virus', name: '<i>SEN virus</i> (SENV-D and SENV-H strains)', gram: 'ssDNA (-/+), family Anelloviridae', shape: 'small, non-enveloped circular DNA virus' },
        epidemiology: {
          incidence: 'Present in 10–20% of healthy blood donors, and up to 40–60% of transfused patients, hemodialysis patients, and PWID.',
          risk_groups: ['Transfusion recipients', 'Hemodialysis patients', 'People who inject drugs (PWID)', 'General population'],
          seasonality: 'None',
          transmission: 'Parenteral (transfusion, blood, needle stick), non-parenteral (fecal-oral, vertical)'
        },
        pathomechanism: {
          steps: [
            'Transmitted via blood, establishing persistent viremia.',
            'DNA detectable in hepatocytes and peripheral cells, but does NOT cause cytopathology or necroinflammation.',
            'Rigorous prospective and retrospective clinical studies demonstrate that SENV does NOT increase the risk of post-transfusion hepatitis, cryptogenic hepatitis, or cirrhosis.',
            'Commensal member of the human anellovirome.'
          ],
          virulence_factors: ['No proven virulence factors.']
        },
        clinical: {
          incubation: 'Not applicable',
          onset: 'Asymptomatic',
          symptoms: [
            { name: 'Asymptomatic carriage', description: 'Does not cause acute or chronic liver disease. Historical associations with post-transfusion hepatitis were disproven.', severity: 'mild' }
          ],
          physical_exam: ['Physical examination completely normal'],
          complications: ['No proven hepatic or systemic complications.']
        },
        diagnostics: {
          laboratory: [{ test: 'ALT / AST', finding: 'Within normal limits', interpretation: 'No relevant liver cell damage' }],
          imaging: [{ modality: 'Ultrasound', finding: 'Normal', significance: '-' }],
          microbiology: [
            { test: 'SENV-D / SENV-H PCR', finding: 'DNA detection', significance: 'Research tool; not clinically indicated' }
          ]
        },
        differential: [
          { disease: 'Post-transfusion hepatitis (HCV, HBV, CMV, EBV)', distinguishing: 'Serology and specific PCR assays' }
        ],
        therapy: {
          empirical: {},
          targeted: 'No treatment required.',
          supportive: [],
          prevention: ['Donor screening for SENV is not indicated.']
        },
        prognosis: {
          mortality: 'Excellent (non-pathogenic virus).',
          prognostic_scores: [],
          factors: '-'
        }
      }
    ]
  },
  urinary_tract: {
    name: 'Urinary Tract Infections',
    icon: '🚽',
    color: '#3b82f6',
    diseases: [
      {
        id: 'cystitis',
        name: 'Localised Urinary Tract Infection: Cystitis',
        pathogen: { type: 'Bacterium', name: '<i>Escherichia coli</i> (75-95%)', gram: 'Gram-negative', shape: 'rod' },
        epidemiology: {
          incidence: '50% of women at least once in their lifetime',
          risk_groups: ['Sexually active women', 'Postmenopause', 'Pregnancy', 'Diabetes', 'Catheter use'],
          seasonality: 'None',
          transmission: 'Ascending infection (perineal flora)'
        },
        pathomechanism: {
          steps: [
            'Colonization: Gut bacteria (mainly E. coli) colonize the periurethral area and vaginal introitus.',
            'Ascension: Bacteria ascend through the urethra into the bladder (shorter urethra in women predisposes).',
            'Adherence and Invasion: Bacteria adhere to the bladder urothelium using P-fimbriae, avoiding washout by urine, and then invade cells.',
            'Inflammation: Bacterial multiplication and toxins (e.g., hemolysin) trigger an inflammatory response, causing mucosal hyperemia, edema, and symptoms.'
          ],
          virulence_factors: ['P-fimbriae (adherence)', 'Hemolysin', 'Aerobactin (iron uptake)']
        },
        clinical: {
          incubation: 'Variable',
          onset: 'Sudden',
          symptoms: [
            { name: 'Dysuria', description: 'Burning, stinging sensation during urination caused by irritation of the inflamed urethra and bladder neck.', severity: 'moderate' },
            { name: 'Frequency', description: 'Frequent voiding of small amounts of urine due to bladder wall irritation and reduced capacity.', severity: 'moderate' },
            { name: 'Urgency', description: 'Sudden, compelling urge to urinate that is difficult to defer (risk of urge incontinence).', severity: 'moderate' },
            { name: 'Suprapubic pain', description: 'Pressure or pain felt in the lower abdomen, above the pubic bone.', severity: 'mild' },
            { name: 'Hematuria', description: 'Macroscopic bloody urine (approx. 30%), often at the end of urination (terminal hematuria), due to bleeding from the hyperemic mucosa.', severity: 'mild' },
            { name: 'Atypical elderly presentation', description: 'Older patients may have fewer urinary symptoms and may present with confusion, delirium, or falls.', severity: 'mild' }
          ],
          physical_exam: [
            'Suprapubic tenderness',
            'Fever is usually ABSENT (if present, suspect pyelonephritis!)',
            'Flank is not tender',
            'Absence of vaginal discharge (increases probability of cystitis)',
            'In elderly or diabetic patients exam may be non-specific and fever may be absent'
          ],
          complications: ['Ascending pyelonephritis', 'Recurrent cystitis']
        },
        diagnostics: {
          laboratory: [
            { test: 'Urine dipstick', finding: 'Leukocyte esterase+, Nitrite+', interpretation: 'High positive predictive value' },
            { test: 'Urine sediment', finding: 'Pyuria (>10 WBC/field)', interpretation: 'Common, but not specific' }
          ],
          imaging: [
            { modality: 'None', finding: 'Not necessary', significance: 'Except for atypical symptoms or persistence' }
          ],
          microbiology: [
            { test: 'Urine culture', finding: '≥10^3 CFU/ml', significance: 'Recommended only in complicated, recurrent, or atypical cases (EAU 2025)' }
          ]
        },
        differential: [
          { disease: 'Vaginitis', distinguishing: 'Discharge, itching, external dysuria' },
          { disease: 'Urethritis (STD)', distinguishing: 'New partner, gradual onset, pyuria with sterile culture' },
          { disease: 'Interstitial cystitis', distinguishing: 'Chronic, negative culture' }
        ],
        therapy: {
          empirical: {
            outpatient: [
              { drug: 'Fosfomycin trometamol', dose: '3g PO', duration: 'Single dose', note: 'First choice (EAU 2025)' },
              { drug: 'Nitrofurantoin', dose: '2x100mg PO', duration: '5 days', note: 'First choice (EAU 2025)' },
              { drug: 'Pivmecillinam', dose: '3x400mg PO', duration: '3-5 days', note: 'First choice (EAU 2025)' }
            ],
            inpatient: [
              { drug: 'Does not require hospital treatment', dose: '-', duration: '-', note: 'Except complications' }
            ],
            icu: [
              { drug: '-', dose: '-', duration: '-', note: '-' }
            ]
          },
          targeted: 'Based on culture. Fluoroquinolones (Ciprofloxacin, Levofloxacin) are NOT recommended empirically for uncomplicated cystitis!',
          supportive: ['Ample fluid intake', 'Frequent urination', 'NSAID for pain relief'],
          prevention: ['Behavioral: Ample fluid intake, postcoital voiding', 'Non-antibiotic (EAU 2025): Topical estrogen (postmenopause), OM-89 immunostimulation, D-mannose, Bladder instillation', 'Antibiotic prophylaxis (last resort): Nitrofurantoin 50-100mg at night or Fosfomycin 3g every 10 days']
        },
        prognosis: {
          mortality: 'Zero',
          prognostic_scores: ['None'],
          factors: 'Tendency to recur'
        }
      },
      {
        id: 'pyelonephritis',
        name: 'Localised Urinary Tract Infection: Pyelonephritis',
        pathogen: { type: 'Bacterium', name: '<i>Escherichia coli</i> (80%)', gram: 'Gram-negative', shape: 'rod' },
        epidemiology: {
          incidence: 'Common complication of untreated cystitis',
          risk_groups: ['Women', 'Pregnancy', 'Obstruction (stone, prostate)', 'Renal developmental anomaly', 'Diabetes'],
          seasonality: 'None',
          transmission: 'Ascending infection (95%), rarely hematogenous'
        },
        pathomechanism: {
          steps: [
            'Ascending Infection: Bacteria ascend from the bladder up the ureter to the renal pelvis (often facilitated by vesicoureteral reflux).',
            'Parenchymal Invasion: Pathogens invade the renal parenchyma, primarily the medulla.',
            'Inflammatory Response: A vigorous acute inflammatory reaction (neutrophil infiltration) is triggered against the bacteria, causing tissue edema, microabscesses, and tubular damage.',
            'Systemic Effect: Inflammatory mediators entering the circulation cause fever and systemic symptoms.'
          ],
          virulence_factors: ['P-fimbriae', 'Endotoxin', 'Capsule']
        },
        clinical: {
          incubation: 'Days after cystitis',
          onset: 'Sudden',
          symptoms: [
            { name: 'Fever and Chills', description: 'High fever (>38°C) with shaking chills is the hallmark of renal parenchymal infection and indicates a systemic inflammatory response.', severity: 'severe' },
            { name: 'Flank Pain', description: 'Dull, constant pain in the kidney area caused by stretching of the renal capsule; it may be unilateral or bilateral.', severity: 'severe' },
            { name: 'Gastrointestinal Symptoms', description: 'Nausea, vomiting, and appetite loss are common because renal inflammation can trigger visceral reflexes.', severity: 'moderate' },
            { name: 'Lower Urinary Tract Symptoms', description: 'Dysuria and frequency often precede fever but may be absent in 30-50% of cases; absence of bladder symptoms does not exclude an upper UTI.', severity: 'moderate' },
            { name: 'Atypical Presentation', description: 'Elderly or immunocompromised patients may present primarily with confusion, weakness, or functional decline rather than classic symptoms.', severity: 'moderate' }
          ],
          physical_exam: [
            'Costovertebral angle tenderness (Giordano\'s sign)',
            'Fever and tachycardia',
            'Abdominal tenderness may be present but is less specific',
            'The exam can be subtle in older or immunocompromised patients'
          ],
          complications: ['Renal abscess', 'Perinephric abscess', 'Urosepsis', 'Papillary necrosis', 'Chronic renal failure (recurrent)']
        },
        diagnostics: {
          laboratory: [
            { test: 'CBC', finding: 'Leukocytosis, left shift', interpretation: 'Systemic inflammation' },
            { test: 'CRP/PCT', finding: 'Significantly elevated', interpretation: 'Bacterial infection' },
            { test: 'Urinalysis', finding: 'Leukocyturia, bacteriuria, white blood cell casts', interpretation: 'Upper urinary tract origin' },
            { test: 'Renal function', finding: 'Creatinine may be elevated', interpretation: 'Acute kidney injury' }
          ],
          imaging: [
            { modality: 'Abdominal/pelvic CT', finding: 'Renal enlargement, perinephric fluid, wedge-shaped hypodensity', significance: 'Gold standard to rule out complications (EAU 2025)' },
            { modality: 'Renal US', finding: 'Obstruction, abscess', significance: 'Radiation-free alternative' }
          ],
          microbiology: [
            { test: 'Urine culture', finding: '≥10^4 CFU/ml', significance: 'Always take! (EAU 2025)' },
            { test: 'Blood culture', finding: 'Positive', significance: 'Recommended on hospital admission' }
          ]
        },
        differential: [
          { disease: 'Kidney stone', distinguishing: 'Colicky pain, no fever (if no infection), hematuria dominates' },
          { disease: 'Acute abdominal conditions', distinguishing: 'Appendicitis, cholecystitis (abdominal status, US)' },
          { disease: 'Pelvic inflammatory disease (PID)', distinguishing: 'Gynecological exam, discharge' }
        ],
        therapy: {
          empirical: {
            outpatient: [
              { drug: 'Cefuroxime axetil', dose: '2x500mg PO', duration: '7 days', note: 'no activity against Enterococcus' },
              { drug: 'Levofloxacin', dose: '1x750mg PO', duration: '5 days', note: 'Only an alternative if E. coli resistance <10% (EAU 2025)' },
              { drug: 'Ceftibuten/Cefixime', dose: 'PO', duration: '10 days', note: 'If quinolone cannot be given (less effective)' }
            ],
            inpatient: [
              { drug: 'Ceftriaxone', dose: '1x1-2g IV', duration: '10-14 days', note: 'First choice' },
              { drug: 'Ciprofloxacin', dose: '2x400mg IV', duration: '10-14 days', note: 'Alternative if E. coli resistance <10% (EAU 2025)' },
              { drug: 'Gentamicin + Ampicillin', dose: 'IV', duration: '', note: 'In severe cases' }
            ],
            icu: [
              { drug: 'Piperacillin/tazobactam', dose: '4x4.5g IV', duration: '', note: 'Urosepsis, obstruction' },
              { drug: 'Meropenem', dose: '3x1g IV', duration: '', note: 'Suspicion of ESBL' }
            ]
          },
          targeted: 'Based on antibiogram. ESBL is common!',
          supportive: ['Fluid replacement', 'Antipyretics', 'Resolution of obstruction (catheter, stent)'],
          prevention: ['Proper treatment of cystitis', 'Correction of anatomical abnormalities']
        },
        prognosis: {
          mortality: 'Low (<1%), but 10-20% in urosepsis',
          prognostic_scores: ['qSOFA'],
          factors: 'Old age, obstruction, resistant pathogen'
        }
      },
      {
        id: 'complicated_uti',
        name: 'Systemic Urinary Tract Infection',
        pathogen: { type: 'Bacterium', name: '<i>E. coli, Enterococcus, Pseudomonas, Klebsiella, Proteus</i>', gram: 'Mixed', shape: 'Mixed' },
        epidemiology: {
          incidence: 'Common in hospital settings and urological patients',
          risk_groups: ['Catheter users', 'Men', 'Pregnant women', 'Anatomical/functional abnormality', 'Renal failure', 'Immunosuppression'],
          seasonality: 'None',
          transmission: 'Ascending, catheter-associated, hematogenous'
        },
        pathomechanism: {
          steps: [
            'Predisposing Factor: Anatomical (e.g., stricture, stone) or functional (e.g., neurogenic bladder) abnormality, or presence of a foreign body (catheter) impedes urine flow and bacterial washout.',
            'Biofilm Formation: Bacteria (e.g., Proteus, Pseudomonas) form a biofilm layer on the catheter or stone, protecting them from antibiotics and the immune system.',
            'Persistence: Infection is difficult to eradicate; selection of resistant strains and recurrent infection are common.'
          ],
          virulence_factors: ['Biofilm', 'Multidrug resistance', 'Urease (Proteus)']
        },
        clinical: {
          incubation: 'Variable',
          onset: 'Variable (can be oligosymptomatic)',
          symptoms: [
            { name: 'Lower Urinary Tract Symptoms', description: 'Dysuria, frequency, and urgency may occur but are not always dominant; the infection can involve multiple segments of the urinary tract.', severity: 'moderate' },
            { name: 'Upper Urinary Tract/Local Pain', description: 'Suprapubic or flank pain may be present, especially when obstruction or renal involvement exists.', severity: 'moderate' },
            { name: 'Systemic Inflammation', description: 'Fever, chills and tachycardia point to a larger pathogen burden and a systemic host response.', severity: 'severe' },
            { name: 'Sepsis Signs', description: 'Hypotension, tachypnea, altered mental status, or oliguria may develop in urosepsis and require urgent source control.', severity: 'severe' },
            { name: 'Oligosymptomatic', description: 'Catheterized, neurogenic bladder, or immunosuppressed patients often lack classic symptoms, so lab and vital sign monitoring is essential.', severity: 'mild' }
          ],
          physical_exam: [
            'Often unremarkable, especially in catheterized patients',
            'Suprapubic or flank tenderness',
            'Presence of a catheter or other urinary device',
            'Fever or hypothermia',
            'Hypotension, tachypnea, or altered mental status in severe cases'
          ],
          complications: ['Urosepsis', 'Renal abscess', 'Renal failure', 'Recurrence', 'Catheter obstruction']
        },
        diagnostics: {
          laboratory: [
            { test: 'Urine culture', finding: 'Women: ≥10^5 CFU/ml, Men: ≥10^4 CFU/ml', interpretation: 'Diagnostic thresholds (EAU 2025)' },
            { test: 'Catheter urine', finding: '≥10^4 CFU/ml', interpretation: 'Significant bacteriuria' },
            { test: 'Renal function', finding: 'Check creatinine', interpretation: 'Obstruction/damage' }
          ],
          imaging: [
            { modality: 'CT urography', finding: 'Anatomical/functional abnormality', significance: 'MANDATORY to clarify predisposing factor' }
          ],
          microbiology: [
            { test: 'Culture + Susceptibility', finding: 'Essential', significance: 'Basis for targeted therapy' }
          ]
        },
        differential: [
          { disease: 'Uncomplicated UTI', distinguishing: 'No risk factors, no systemic signs' },
          { disease: 'Acute prostatitis', distinguishing: 'Perineal pain, prostate tenderness, urinary retention' },
          { disease: 'Urosepsis', distinguishing: 'Hypotension, altered mental status, severe systemic signs' },
          { disease: 'Catheter-associated bacteriuria', distinguishing: 'Often asymptomatic with catheter, positive culture without systemic response' }
        ],
        therapy: {
          empirical: {
            outpatient: [
              { drug: 'Cefuroxime axetil', dose: '2x500mg PO', duration: '7-14 days', note: 'no activity against Enterococcus' },
              { drug: 'Ciprofloxacin', dose: '2x500-750mg PO', duration: '7-14 days', note: 'Only if no fluoroquinolone treatment in the last 6 months and E. coli resistance <10% (EAU 2025)' },
              { drug: 'Levofloxacin', dose: '1x750mg PO', duration: '7-14 days', note: 'Alternative if E. coli resistance <10% (EAU 2025)' },
              { drug: 'Ceftibuten/Cefixime', dose: 'PO', duration: '10-14 days', note: 'If quinolone cannot be given' }
            ],
            inpatient: [
              { drug: 'Ceftriaxone', dose: '1x1-2g IV', duration: '10-14 days', note: 'In severe cases' },
              { drug: 'Piperacillin/tazobactam', dose: '3x4.5g IV', duration: '10-14 days', note: 'Suspicion of Pseudomonas/previous AB treatment' },
              { drug: 'Carbapenem (Meropenem)', dose: '3x1g IV', duration: '10-14 days', note: 'ESBL risk or septic shock' },
              { drug: 'Amikacin/Gentamicin', dose: 'IV', duration: 'As an adjunct', note: 'Synergism' }
            ],
            icu: [
              { drug: 'Broad spectrum (Carbapenem + Amikacin)', dose: 'IV', duration: '', note: 'Urosepsis' }
            ]
          },
          targeted: 'Correction based on culture. Resolution of obstruction (catheter change, stent, nephrostomy) is essential!',
          supportive: ['Fluid replacement', 'Antipyretics'],
          prevention: ['Catheter care (closed system, prompt removal)', 'Elimination of obstruction', 'Avoidance of treating asymptomatic bacteriuria']
        },
        prognosis: {
          mortality: '10-30% in urosepsis',
          prognostic_scores: ['qSOFA', 'SOFA'],
          factors: 'Underlying disease, resistance, source control'
        }
      },
      {
        id: 'prostatitis',
        name: 'Bacterial Prostatitis',
        pathogen: { type: 'Bacterium', name: '<i>E. coli, Klebsiella, Proteus, Enterococcus, Pseudomonas</i>', gram: 'Mixed', shape: 'Mixed' },
        epidemiology: {
          incidence: '50% of men experience symptoms in their lifetime',
          risk_groups: ['Young/middle-aged men', 'Catheterization', 'Urological procedure (biopsy)', 'HIV', 'Diabetes'],
          seasonality: 'None',
          transmission: 'Ascending (reflux), hematogenous, lymphogenic, direct (biopsy)'
        },
        pathomechanism: {
          steps: [
            'Route of Infection: Most commonly, bacteria enter the prostatic ducts via intraprostatic reflux of infected urine.',
            'Inflammation: In acute cases, edema and microabscesses develop in the glands, causing swelling and tension of the prostate.',
            'Chronicity: Bacteria can form biofilms on prostatic stones or in ductal channels, maintaining recurrent infections.'
          ],
          virulence_factors: ['Biofilm', 'Anatomical location (poor AB penetration)']
        },
        clinical: {
          incubation: 'Variable',
          onset: 'Acute (ABP) or Chronic (CBP)',
          symptoms: [
            { name: 'Acute: Systemic Symptoms', description: 'Sudden onset of high fever, chills, myalgia, malaise (flu-like onset).', severity: 'severe' },
            { name: 'Pain', description: 'Characteristic perineal, rectal, lower abdominal pain, radiating to testes and penis.', severity: 'moderate' },
            { name: 'LUTS (Lower Urinary Tract Symptoms)', description: 'Marked dysuria, frequency, urgent need to void.', severity: 'moderate' },
            { name: 'Obstruction', description: 'The swollen prostate compresses the urethra, which can cause difficulty voiding, weak stream, or complete urinary retention.', severity: 'severe' },
            { name: 'Urinary retention', description: 'Severe obstruction may lead to bladder overdistension and acute urinary retention.', severity: 'severe' },
            { name: 'Chronic Symptoms', description: 'Milder, recurrent complaints: pelvic discomfort, recurrent urinary tract infections, painful ejaculation.', severity: 'mild' }
          ],
          physical_exam: [
            'Digital rectal exam (DRE):',
            'Acute: Swollen, warm, EXTREMELY tender prostate (Massage FORBIDDEN - risk of bacteremia!)',
            'Chronic: May be normal or slightly tender, not swollen',
            'Distended bladder on exam if urinary retention is present'
          ],
          complications: ['Prostate abscess', 'Urosepsis', 'Chronicity', 'Epididymitis', 'Urinary retention', 'Sexual dysfunction']
        },
        diagnostics: {
          laboratory: [
            { test: 'Urinalysis', finding: 'Pyuria, bacteriuria', interpretation: 'Positive' },
            { test: 'CBC/CRP', finding: 'Elevated (Acute)', interpretation: 'Systemic inflammation' },
            { test: 'PSA', finding: 'Elevated', interpretation: 'Due to inflammation (not for cancer diagnosis in acute phase!)' }
          ],
          imaging: [
            { modality: 'Transrectal US (TRUS)', finding: 'Abscess (hypoechoic area)', significance: 'Only if no improvement on treatment or suspicion of abscess' }
          ],
          microbiology: [
            { test: 'Acute: Urine culture', finding: 'Midstream urine', significance: 'Prostate massage FORBIDDEN!' },
            { test: 'Chronic: Meares-Stamey test', finding: '4-glass test or 2-glass test (pre/post massage)', significance: 'Gold standard (EAU 2025)' }
          ]
        },
        differential: [
          { disease: 'Cystitis', distinguishing: 'No fever, no prostate tenderness' },
          { disease: 'BPH', distinguishing: 'No signs of infection, slow progression' },
          { disease: 'Chronic pelvic pain syndrome (CPPS)', distinguishing: 'Negative culture, chronic pain' },
          { disease: 'Prostate cancer', distinguishing: 'PSA, DRE (nodular), biopsy' }
        ],
        therapy: {
          empirical: {
            outpatient: [
              { drug: 'Levofloxacin', dose: '1x500-750mg PO', duration: '2-4 weeks (Acute), 4-6 weeks (Chronic)', note: 'EAU 2025: First choice (good penetration)' },
              { drug: 'Ciprofloxacin', dose: '2x500mg PO', duration: '2-4 weeks (Acute), 4-6 weeks (Chronic)', note: 'EAU 2025: First choice' },
              { drug: 'Cotrimoxazole', dose: '2x960mg PO', duration: '4-6 weeks', note: 'Alternative' }
            ],
            inpatient: [
              { drug: 'Ceftriaxone', dose: '1-2g IV', duration: '14 days', note: 'In severe acute cases (then switch to PO)' },
              { drug: 'Piperacillin/tazobactam', dose: '3x4.5g IV', duration: '', note: 'Urosepsis/suspicion of Pseudomonas' },
              { drug: 'Gentamicin', dose: '5-7mg/kg IV', duration: '', note: 'As an adjunct (synergism)' }
            ],
            icu: [
              { drug: 'Meropenem', dose: '3x1g IV', duration: '', note: 'Septic shock/ESBL' }
            ]
          },
          targeted: 'Fluoroquinolones (first choice in chronic). Macrolides (suspicion of Chlamydia). Fosfomycin (MDR - controversial penetration).',
          supportive: ['NSAID for pain relief', 'Alpha-blocker (Tamsulosin) to relieve symptoms', 'Suprapubic catheter (in retention, urethral should be avoided in acute inflammation!)'],
          prevention: ['Early treatment of UTIs', 'Prostate biopsy prophylaxis: Targeted (based on rectal swab) or Fosfomycin/Ceftriaxone (Fluoroquinolones should be avoided!)']
        },
        prognosis: {
          mortality: 'Acute: low (but risk of sepsis); Chronic: impairs quality of life, difficult to cure (recurrence common)',
          prognostic_scores: ['None'],
          factors: 'Biofilm, resistance, anatomy, transition to CPPS'
        }
      },
      {
        id: 'asymptomatic_bacteriuria',
        name: 'Asymptomatic Bacteriuria',
        pathogen: { type: 'Bacterium', name: '<i>E. coli, Enterococcus, GBS</i>, etc.', gram: 'Variable', shape: 'Variable' },
        epidemiology: {
          incidence: 'Common (women 3-5%, elderly 10-50%, catheterized 100%)',
          risk_groups: ['Elderly', 'Diabetes', 'Catheter use', 'Pregnancy'],
          seasonality: 'None',
          transmission: 'Endogenous colonization'
        },
        pathomechanism: {
          steps: [
            'Colonization: Bacteria colonize the urinary tract but lack virulence factors (e.g., specific fimbriae) that would trigger tissue invasion or inflammation.',
            'Commensalism: A state of equilibrium develops between the bacteria and the host, without symptoms.',
            'Protective Effect: Colonizing strains may compete with more virulent pathogens, potentially having a protective effect.'
          ],
          virulence_factors: ['Reduced virulence']
        },
        clinical: {
          incubation: '-',
          onset: 'Asymptomatic',
          symptoms: [
            { name: 'Asymptomatic', description: 'The patient has no urinary complaints (no dysuria, no fever, no pain). Bacteriuria is an incidental finding.', severity: 'mild' }
          ],
          physical_exam: [
            'Negative',
            'Cloudy/foul-smelling urine alone is not diagnostic and does not require treatment!',
            'No suprapubic or flank tenderness'
          ],
          complications: ['Unnecessary antibiotic treatment → resistance', 'Pyelonephritis (risk only in pregnancy/procedure)']
        },
        diagnostics: {
          laboratory: [
            { test: 'Urine culture', finding: '≥10^5 CFU/ml (same strain)', interpretation: 'Women: 2 consecutive samples, Men: 1 sample (EAU 2025)' },
            { test: 'Catheterized sample', finding: '≥10^5 CFU/ml', interpretation: 'One sample is sufficient' },
            { test: 'Urine sediment', finding: 'Pyuria is often present', interpretation: 'Does NOT indicate treatment without symptoms!' }
          ],
          microbiology: [
            { test: 'Culture', finding: 'Positive', significance: 'Only if screening is indicated (e.g., pregnancy, urological procedure)' }
          ]
        },
        differential: [
          { disease: 'Cystitis', distinguishing: 'Presence of symptoms (dysuria, urgency)' },
          { disease: 'Contamination', distinguishing: 'Low colony count, mixed flora' }
        ],
        therapy: {
          empirical: {
            outpatient: [
              { drug: 'NO treatment', dose: '-', duration: '-', note: 'General rule (not even in elderly, diabetics, catheterized patients!)' }
            ],
            inpatient: [
              { drug: 'NO treatment', dose: '-', duration: '-', note: 'Except indications' }
            ]
          },
          targeted: 'Only if indicated (Pregnancy, Urological procedure with mucosal injury). In pregnancy: Fosfomycin, Nitrofurantoin, Cephalosporin.',
          supportive: ['Education (urine smell/color does not warrant AB)'],
          prevention: ['Avoid unnecessary screening and treatment', 'Catheter care']
        },
        prognosis: {
          mortality: 'Does not increase mortality even if untreated',
          prognostic_scores: ['None'],
          factors: '-'
        }
      }
    ]
  },
  intraabdominal: {
    name: 'Intra-abdominal Infections',
    icon: window.diseaseMetadata?.intraabdominal?.icon || '🩺',
    color: window.diseaseMetadata?.intraabdominal?.color || '#16a34a',
    tables: [],
    diseases: [
      {
        id: 'primary_bacterial_peritonitis',
        name: 'Spontaneous Bacterial Peritonitis (SBP)',
        pathogen: { type: 'Bacteria', name: '<i>E. coli, Klebsiella, S. pneumoniae</i>', gram: 'Variable', shape: 'Variable' },
        epidemiology: {
          incidence: 'Common in cirrhotic patients with ascites',
          risk_groups: ['Liver cirrhosis with ascites', 'Nephrotic syndrome'],
          seasonality: 'None',
          transmission: 'Translocation of endogenous flora'
        },
        pathomechanism: {
          steps: [
            'Intestinal flora translocates across the gut wall into mesenteric lymph nodes and bloodstream.',
            'Portal hypertension and impaired immunity allow bacteria to colonize ascitic fluid.',
            'An inflammatory response develops in the peritoneum.'
          ]
        },
        clinical: {
                incubation: 'Variable',
                onset: 'Acute or subacute',
                symptoms: [
                  { name: 'Abdominal pain', description: 'Diffuse, mild to moderate abdominal pain, tenderness.', severity: 'moderate' },
                  { name: 'Fever', description: 'Low-grade or high fever.', severity: 'moderate' },
                  { name: 'Hepatic encephalopathy', description: 'Worsening mental status is often the first sign in cirrhotic patients.', severity: 'severe' }
                ],
                physical_exam: ['Fever', 'Abdominal tenderness', 'Signs of ascites', 'Encephalopathy'],
                complications: ['Sepsis', 'Hepatorenal syndrome', 'Progression of liver disease']
              },
        diagnostics: {
                laboratory: [
                  { test: 'Ascitic fluid analysis', finding: 'PMN count > 250/mm3', interpretation: 'Diagnostic for SBP' },
                  { test: 'CBC', finding: 'Leukocytosis, elevated CRP', interpretation: 'Inflammation' }
                ],
                microbiology: [
                  { test: 'Ascitic fluid culture', finding: 'Monobacterial (mostly E. coli)', significance: 'Pathogen identification' }
                ],
                differential: [
                  { disease: 'Secondary peritonitis', distinguishing: 'Polymicrobial culture, very high ascitic protein' }
                ]
              },
        therapy: {
                empirical: {
                  inpatient: [
                    { drug: 'Ceftriaxone', dose: '2g IV daily', duration: '5-7 days', note: 'First line' }
                  ]
                },
                targeted: 'Based on culture and susceptibilities',
                supportive: ['Albumin infusion (to prevent renal failure)', 'Withhold diuretics'],
                prevention: ['Antibiotic prophylaxis (Norfloxacin or TMP-SMX)']
              },
        guidelines: {
                diagnosis: [
                  'Diagnostic paracentesis for all hospitalized cirrhotic patients with ascites.',
                  'Diagnosis: ascitic PMN > 250/mm3.'
                ],
                treatment_indications: [
                  'Empiric antibiotics should be started immediately if PMN > 250/mm3.'
                ],
                first_line: ['Ceftriaxone or Cefotaxime IV.'],
                supportive: ['IV Albumin infusion reduces the risk of hepatorenal syndrome.'],
                prevention: ['Prophylaxis is recommended after prior SBP or during GI bleeding.']
              },
        prognosis: {
                mortality: '10-30% during hospitalization',
                factors: 'Hepatorenal syndrome worsens prognosis.'
              }
      },
      {
        id: 'pyogenic_liver_abscess',
        name: 'Pyogenic Liver Abscess',
        pathogen: { type: 'Mixed (Bacteria)', name: '<i>E. coli, Klebsiella, Streptococcus spp., Anaerobes</i>', gram: 'Variable', shape: 'Variable' },
        epidemiology: {
          incidence: 'Most common visceral abscess',
          risk_groups: ['Biliary tract disease', 'Malignancy', 'Diabetes', 'Intra-abdominal infection (appendicitis, diverticulitis)'],
          seasonality: 'None',
          transmission: 'Biliary ascending, portal vein, or hematogenous spread'
        },
        pathomechanism: {
          steps: [
            'Bacteria usually enter the liver via the biliary tree (cholangitis) or portal vein (pylephlebitis) from abdominal infections.',
            'Pathogens colonize the liver parenchyma, causing inflammation, local necrosis, and pus collection.',
            'K. pneumoniae (K1/K2 hypermucoviscous) syndrome in Asian patients can cause cryptogenic abscesses and metastatic infections (endophthalmitis).'
          ]
        },
        clinical: {
          incubation: 'Variable',
          onset: 'Often insidious, subacute',
          symptoms: [
            { name: 'Fever', description: 'Fever, chills often the main symptom.', severity: 'moderate' },
            { name: 'Right upper quadrant pain', description: 'Dull pain, possibly with pleuritic symptoms.', severity: 'moderate' },
            { name: 'Weight loss, malaise', description: 'In subacute cases.', severity: 'mild' }
          ],
          physical_exam: ['Right upper quadrant tenderness', 'Hepatomegaly', 'Jaundice (rare, mostly if biliary obstruction)'],
          complications: ['Rupture (peritonitis, pleural empyema)', 'Sepsis', 'Metastatic infection (K. pneumoniae)']
        },
        diagnostics: {
          laboratory: [
            { test: 'CBC', finding: 'Leukocytosis, anemia', interpretation: 'Inflammation' },
            { test: 'Liver enzymes', finding: 'Elevated ALP, GGT', interpretation: 'Space-occupying liver lesion' }
          ],
          imaging: [
            { modality: 'Abdominal US', finding: 'Hypoechoic lesion, fluid level', significance: 'First-line imaging' },
            { modality: 'Abdominal CT', finding: 'Rim-enhancing hypodense lesion', significance: 'Accurate localization, multiple abscesses' }
          ],
          microbiology: [
            { test: 'Abscess aspiration/drainage', finding: 'Positive culture', significance: 'Diagnostic and therapeutic' },
            { test: 'Blood culture', finding: 'Positive in 50%', significance: 'Always obtain' }
          ],
          differential: [
            { disease: 'Amoebic liver abscess', distinguishing: 'E. histolytica serology, travel history' },
            { disease: 'Echinococcal cyst', distinguishing: 'Serology, US appearance, ASPIRATION DANGEROUS' },
            { disease: 'Hepatocellular carcinoma', distinguishing: 'Tumor markers, CT appearance' }
          ]
        },
        therapy: {
          empirical: {
            inpatient: [
              { drug: 'Ceftriaxone + Metronidazole', dose: '2g IV daily + 500mg IV q8h', duration: '2-4 weeks', note: 'Standard' },
              { drug: 'Piperacillin-Tazobactam', dose: '4.5g IV q6h-q8h', duration: '2-4 weeks', note: 'Severe / Biliary source' }
            ]
          },
          targeted: 'Based on culture, followed by oral step-down (Ciprofloxacin/Amoxicillin-Clavulanate + Metronidazole) for 4-6 weeks.',
          supportive: ['Percutaneous drainage (first choice for source control!)'],
          prevention: ['Early treatment of biliary and intra-abdominal infections']
        },
        guidelines: {
          diagnosis: [
            'US/CT guided diagnostic and therapeutic aspiration/drainage is essential for microbiology.',
            'Rule out amoebic and echinococcal etiology with serology.'
          ],
          treatment_indications: [
            'Small (<3-5 cm) abscesses can be treated with antibiotics alone, larger ones require drainage.'
          ],
          first_line: ['Combination antibiotics (Ceftriaxone+Metronidazole) + Percutaneous drainage.'],
          supportive: ['Fluid resuscitation, analgesia.'],
          prevention: ['No specific prophylaxis, treat underlying conditions.']
        },
        prognosis: {
          mortality: '5-15% (with proper drainage)',
          factors: 'Multiple abscesses, biliary source (malignancy), delayed diagnosis worsen prognosis.'
        }
      },
      {
        id: 'cholangitis',
        name: 'Ascending Cholangitis',
        pathogen: { type: 'Mixed (Bacteria)', name: '<i>E. coli, Klebsiella, Enterococcus spp., Anaerobes (less common)</i>', gram: 'Variable', shape: 'Variable' },
        epidemiology: {
          incidence: 'Secondary to biliary obstruction',
          risk_groups: ['Choledocholithiasis (gallstones)', 'Malignant biliary stricture', 'Post-ERCP'],
          seasonality: 'None',
          transmission: 'Bacteria ascending from duodenum in the setting of obstruction'
        },
        pathomechanism: {
          steps: [
            'Biliary obstruction (stone, tumor) halts bile flow, increasing biliary pressure.',
            'Stagnant bile becomes infected by bacteria ascending from the intestine.',
            'Elevated pressure forces bacteria and toxins into the bloodstream (severe sepsis).'
          ]
        },
        clinical: {
          incubation: 'Acute',
          onset: 'Sudden, severe',
          symptoms: [
            { name: 'Charcot Triad', description: 'Fever/chills, RUQ pain, Jaundice.', severity: 'severe' },
            { name: 'Reynolds Pentad', description: 'Charcot Triad + Hypotension (shock) + Altered mental status.', severity: 'severe' }
          ],
          physical_exam: ['Jaundice', 'Right upper quadrant tenderness', 'Fever', 'Hypotension'],
          complications: ['Septic shock', 'Liver abscess', 'Acute kidney injury']
        },
        diagnostics: {
          laboratory: [
            { test: 'CBC', finding: 'Leukocytosis with left shift', interpretation: 'Inflammation' },
            { test: 'Liver enzymes', finding: 'Markedly elevated ALP, GGT, bilirubin', interpretation: 'Biliary obstruction' }
          ],
          imaging: [
            { modality: 'Abdominal US', finding: 'Dilated bile ducts, possible stones', significance: 'Initial imaging' },
            { modality: 'MRCP', finding: 'Accurate imaging of stones', significance: 'If US non-diagnostic but suspicion is high' }
          ],
          microbiology: [
            { test: 'Blood culture', finding: 'Often positive', significance: 'Always obtain before ABx' },
            { test: 'Bile culture', finding: 'Polymicrobial', significance: 'Obtained during ERCP drainage' }
          ],
          differential: [
            { disease: 'Acute cholecystitis', distinguishing: 'Jaundice rare, bile ducts not dilated' },
            { disease: 'Pyogenic liver abscess', distinguishing: 'Jaundice less prominent, CT appearance' }
          ]
        },
        therapy: {
          empirical: {
            inpatient: [
              { drug: 'Ceftriaxone + Metronidazole', dose: '2g IV daily + 500mg IV q8h', duration: '4-7 days after obstruction resolved', note: 'Community-acquired, mild/moderate' },
              { drug: 'Piperacillin-Tazobactam', dose: '4.5g IV q6h-q8h', duration: '4-7 days after obstruction resolved', note: 'Severe / Healthcare-associated' }
            ]
          },
          targeted: 'Based on culture, but successful decompression is most critical!',
          supportive: ['Sepsis management, fluid resuscitation'],
          prevention: ['Gallstone removal, stent exchanges']
        },
        guidelines: {
          diagnosis: [
            'Tokyo Guidelines: systemic inflammation, cholestasis, and imaging evidence of biliary disease/dilation.',
            'Presence of Reynolds pentad requires immediate emergency intervention.'
          ],
          treatment_indications: [
            'Immediate broad-spectrum antibiotics AND urgent (within 24h) biliary decompression (ERCP or PTC).'
          ],
          first_line: ['Antibiotics (e.g. Pip/Tazo) AND ERCP with stone extraction/stenting.'],
          supportive: ['ICU admission, vasopressors for shock.'],
          prevention: ['Cholecystectomy after acute episode, ERCP prophylaxis.']
        },
        prognosis: {
          mortality: '5-10% (near 100% without decompression)',
          factors: 'Early recognition and successful decompression are life-saving.'
        }
      },
      {
        id: 'secondary_peritonitis',
        name: 'Secondary Peritonitis',
        pathogen: { type: 'Mixed (Bacteria)', name: '<i>E. coli, Klebsiella, Enterococcus, B. fragilis, anaerobes</i>', gram: 'Variable', shape: 'Variable' },
        epidemiology: {
          incidence: 'Common surgical emergency',
          risk_groups: ['Perforated ulcer', 'Appendicitis', 'Diverticulitis', 'Postoperative bowel surgery'],
          seasonality: 'None',
          transmission: 'Perforation of the gastrointestinal tract'
        },
        pathomechanism: {
          steps: [
            'The continuity of the GI tract wall is disrupted (perforation, necrosis).',
            'Mixed normal flora of the bowel enters the sterile peritoneal cavity.',
            'Intense inflammation (fibrin deposition), loculation (abscess formation), and/or systemic toxicity develops.'
          ]
        },
        clinical: {
          incubation: 'Acute',
          onset: 'Sudden, severe',
          symptoms: [
            { name: 'Abdominal pain', description: 'Sharp, severe pain worsened by movement.', severity: 'severe' },
            { name: 'Fever', description: 'High fever, chills.', severity: 'moderate' },
            { name: 'Ileus symptoms', description: 'Vomiting, inability to pass gas or stool.', severity: 'severe' }
          ],
          physical_exam: ['Board-like rigidity (guarding)', 'Rebound tenderness', 'Absent bowel sounds', 'Tachycardia, hypotension'],
          complications: ['Septic shock', 'Multiorgan failure (MODS)', 'Intra-abdominal abscesses']
        },
              diagnostics: {
          laboratory: [
            { test: 'CBC', finding: 'Marked leukocytosis with left shift', interpretation: 'Severe inflammation' },
            { test: 'Lactate', finding: 'Elevated', interpretation: 'Tissue hypoperfusion, sepsis' }
          ],
          imaging: [
            { modality: 'CT Abdomen', finding: 'Free air in abdomen, fluid collection, abscess', significance: 'Gold standard' },
            { modality: 'Chest X-ray', finding: 'Free air under the diaphragm', significance: 'Rapid initial screen' }
          ],
          microbiology: [
            { test: 'Intraoperative culture', finding: 'Polymicrobial (aerobic + anaerobic)', significance: 'Targeted therapy' },
            { test: 'Blood culture', finding: 'Often positive', significance: 'Confirms sepsis' }
          ],
          differential: [
            { disease: 'Primary peritonitis', distinguishing: 'Ascites, monobacterial, no free air' },
            { disease: 'Acute pancreatitis', distinguishing: 'Elevated lipase, CT appearance' }
          ]
        },
              therapy: {
          empirical: {
            inpatient: [
              { drug: 'Ceftriaxone + Metronidazole', dose: '2g IV daily + 500mg IV q8h', duration: 'Depends on source control', note: 'Mild/Moderate' },
              { drug: 'Piperacillin-Tazobactam', dose: '4.5g IV q6h-q8h', duration: 'Depends on source control', note: 'Severe / Nosocomial' },
              { drug: 'Meropenem', dose: '1g IV q8h', duration: '-', note: 'Septic shock, ESBL risk' }
            ]
          },
          targeted: 'Based on culture, but anaerobic coverage often continued regardless.',
          supportive: ['Sepsis protocol (fluids, vasopressors)'],
          prevention: ['Surgical prophylaxis, early diagnosis and surgery']
        },
              guidelines: {
          diagnosis: [
            'Urgent imaging (CT) to identify free air, fluid, or abscess.',
            'Preoperative labs (lactate) to assess sepsis risk.'
          ],
          treatment_indications: [
            'Surgical source control is the cornerstone of therapy. Antibiotics alone are insufficient!'
          ],
          first_line: ['Source control (surgery) + Broad-spectrum antibiotics (Ceftriaxone/Metronidazole or Pip/Tazo).'],
          supportive: ['Intensive care for septic shock.'],
          prevention: ['Appropriate perioperative antibiotic prophylaxis.']
        },
              prognosis: {
          mortality: '10-50% (higher in delayed diagnosis, elderly, comorbidities)',
          factors: 'Success of source control, severity of sepsis'
        }
            },
            {
              id: 'acute_cholecystitis',
              name: 'Acute Cholecystitis',
              pathogen: { type: 'Mixed (Bacteria)', name: '<i>E. coli, Klebsiella, Enterococcus spp., less commonly anaerobes</i>', gram: 'Variable', shape: 'Variable' },
              epidemiology: {
                incidence: 'Common surgical disease',
                risk_groups: ['Gallstones (Female, >40 years, Obesity, Multiparity)', 'Critically ill patients (Acalculous cholecystitis)'],
                seasonality: 'None',
                transmission: 'Obstruction of the gallbladder neck or cystic duct, followed by secondary bacterial infection'
              },
              pathomechanism: {
                steps: [
                  'A gallstone impacts in the cystic duct, obstructing bile outflow.',
                  'Gallbladder wall distends, becomes ischemic (chemical inflammation).',
                  'Secondary bacterial colonization of the stagnant bile leads to purulent inflammation.',
                  'In acalculous form, biliary stasis and ischemia cause necrosis (in critically ill patients).'
                ]
              },
              clinical: {
                incubation: 'Acute',
                onset: 'Gradually worsening, then constant',
                symptoms: [
                  { name: 'Abdominal pain', description: 'Right upper quadrant (RUQ) or epigastric pain radiating to the right scapula, becoming constant.', severity: 'severe' },
                  { name: 'Nausea, vomiting', description: 'Frequent accompanying symptom.', severity: 'moderate' },
                  { name: 'Fever', description: 'Low-grade or high fever.', severity: 'moderate' }
                ],
                physical_exam: ['Murphy sign (inspiratory arrest upon RUQ palpation)', 'RUQ tenderness', 'Jaundice is usually ABSENT (if present, suspect choledocholithiasis)'],
                complications: ['Gallbladder perforation', 'Biliary peritonitis', 'Empyema of the gallbladder', 'Gangrenous cholecystitis']
              },
              diagnostics: {
                laboratory: [
                  { test: 'CBC', finding: 'Leukocytosis with left shift, elevated CRP', interpretation: 'Inflammation' },
                  { test: 'Liver enzymes', finding: 'Usually normal or mildly elevated', interpretation: 'If ALP/Bilirubin are high, consider common bile duct stone (or Mirizzi syndrome)' }
                ],
                imaging: [
                  { modality: 'Abdominal US', finding: 'Thickened gallbladder wall (>3 mm), pericholecystic fluid, stones, sonographic Murphy sign', significance: 'Gold standard, most sensitive and specific' },
                  { modality: 'Abdominal CT', finding: 'Inflammatory signs', significance: 'Used if complications (perforation, abscess) are suspected' }
                ],
                microbiology: [
                  { test: 'Blood culture', finding: 'Positive in severe cases', significance: 'If sepsis is present' },
                  { test: 'Bile culture', finding: 'Positive (obtained during surgery)', significance: 'In complicated cases' }
                ],
                differential: [
                  { disease: 'Acute cholangitis', distinguishing: 'Jaundice, dilated bile ducts, Reynolds pentad' },
                  { disease: 'Acute pancreatitis', distinguishing: 'Markedly elevated lipase' },
                  { disease: 'Peptic ulcer disease', distinguishing: 'History, gastroscopy' }
                ]
              },
              therapy: {
                empirical: {
                  inpatient: [
                    { drug: 'Ceftriaxone + Metronidazole', dose: '2g IV daily + 500mg IV q8h', duration: 'Until afebrile / surgery', note: 'Mild/Moderate' },
                    { drug: 'Piperacillin-Tazobactam', dose: '4.5g IV q6h-q8h', duration: 'Until afebrile / surgery', note: 'Severe / Nosocomial (acalculous)' }
                  ]
                },
                targeted: 'Based on culture (rarely needed, surgery is definitive).',
                supportive: ['Fluid resuscitation, analgesia (antispasmodics)'],
                prevention: ['Elective cholecystectomy for symptomatic gallstones']
              },
              guidelines: {
                diagnosis: [
                  'Tokyo Guidelines: local inflammation (Murphy sign, pain), systemic inflammation (fever, CRP, WBC), and characteristic imaging (US) findings.'
                ],
                treatment_indications: [
                  'All acute cholecystitis cases require hospital admission and surgical consultation.'
                ],
                first_line: ['Early (ideally within 72 hours) laparoscopic cholecystectomy.'],
                supportive: ['If unfit for surgery (high risk), percutaneous cholecystostomy (drainage) with antibiotics is recommended.'],
                prevention: ['Elective cholecystectomy for symptomatic cholelithiasis.']
              },
              prognosis: {
                mortality: 'Low (1-3%), but higher in the elderly and with perforation',
                factors: 'Early surgery improves prognosis, acalculous form has high mortality (critically ill).'
              }
            },
            {
              id: 'acute_diverticulitis',
              name: 'Acute Diverticulitis',
              pathogen: { type: 'Mixed (Bacteria)', name: '<i>E. coli, B. fragilis, other enteric bacteria</i>', gram: 'Variable', shape: 'Variable' },
              epidemiology: {
                incidence: 'Very common in the elderly (in Western societies)',
                risk_groups: ['>50 years', 'Low-fiber diet', 'Obesity', 'NSAID use'],
                seasonality: 'None',
                transmission: 'Obstruction and inflammation of colonic diverticula (microperforation)'
              },
              pathomechanism: {
                steps: [
                  'Outpouchings (diverticula) form at weak points in the colon wall (diverticulosis).',
                  'A fecalith obstructs the neck of a diverticulum, leading to stasis and bacterial overgrowth.',
                  'Mucosal ischemia causes microperforation, resulting in peridiverticular inflammation or abscess.'
                ]
              },
              clinical: {
                incubation: 'Acute',
                onset: 'Gradually worsening',
                symptoms: [
                  { name: 'Left lower quadrant pain', description: 'Often constant, dull or cramping pain (left-sided appendicitis-like).', severity: 'moderate' },
                  { name: 'Fever', description: 'Low-grade fever, or high fever with chills in severe cases.', severity: 'moderate' },
                  { name: 'Change in bowel habits', description: 'Constipation (more common) or diarrhea, bloating.', severity: 'mild' }
                ],
                physical_exam: ['Left lower quadrant tenderness', 'Palpable mass occasionally (abscess, phlegmon)', 'Increased or (if peritonitis) absent bowel sounds'],
                complications: ['Abscess formation (Hinchey II)', 'Perforation, generalized peritonitis (Hinchey III-IV)', 'Fistula (e.g., colovesical: pneumaturia)', 'Bowel obstruction']
              },
              diagnostics: {
                laboratory: [
                  { test: 'CBC', finding: 'Leukocytosis, elevated CRP', interpretation: 'Marker of inflammation' },
                  { test: 'Urinalysis', finding: 'Sterile pyuria possible', interpretation: 'Inflamed bowel irritating the bladder' }
                ],
                imaging: [
                  { modality: 'CT Abdomen (with contrast)', finding: 'Bowel wall thickening (>4 mm), pericolic fat stranding, possible abscess or free air', significance: 'Gold standard, staging (Hinchey)' },
                  { modality: 'Colonoscopy', finding: 'CONTRAINDICATED in acute phase', significance: 'Risk of perforation! Recommended 6 weeks later to rule out malignancy.' }
                ],
                microbiology: [
                  { test: 'Culture', finding: 'Only from abscess aspiration or surgery', significance: 'Mixed flora' }
                ],
                differential: [
                  { disease: 'Colorectal carcinoma', distinguishing: 'CT, followed by delayed colonoscopy' },
                  { disease: 'IBD (Crohn\'s disease)', distinguishing: 'History, endoscopy' },
                  { disease: 'Gynecological disorders', distinguishing: 'Ovarian cyst rupture, PID (US)' }
                ]
              },
              therapy: {
                empirical: {
                  outpatient: [
                    { drug: 'Amoxicillin-Clavulanate', dose: '1g PO BID', duration: '5-7 days', note: 'Mild, uncomplicated cases' },
                    { drug: 'Ciprofloxacin + Metronidazole', dose: '500mg PO BID + 500mg PO TID', duration: '5-7 days', note: 'If penicillin allergic' }
                  ],
                  inpatient: [
                    { drug: 'Ceftriaxone + Metronidazole', dose: '2g IV daily + 500mg IV q8h', duration: 'Until clinical improvement, then PO', note: 'Moderate/Severe (Hinchey I-II)' },
                    { drug: 'Piperacillin-Tazobactam', dose: '4.5g IV q6h-q8h', duration: 'Perioperative', note: 'Perforation, peritonitis (Hinchey III-IV)' }
                  ]
                },
                targeted: 'Rarely specific, unless drainage is performed.',
                supportive: ['Liquid diet or bowel rest (in severe cases)', 'Analgesia', 'Percutaneous drainage (for abscess >3-4 cm)'],
                prevention: ['High-fiber diet, adequate hydration, weight management']
              },
              guidelines: {
                diagnosis: [
                  'CT scan is recommended to confirm the diagnosis and rule out complications (abscess, perforation).',
                  'Endoscopy is strictly avoided during the acute phase.'
                ],
                treatment_indications: [
                  'In mild, uncomplicated cases (confirmed by CT), antibiotics are increasingly omitted (supportive care only) with close observation.',
                  'Antibiotics: for immunosuppressed, systemic signs of infection, or complicated disease.'
                ],
                first_line: ['Complicated or high-risk: Amoxicillin-Clavulanate or Ceftriaxone+Metronidazole.'],
                supportive: ['Percutaneous drainage for large abscesses. Urgent surgery (Hartmann procedure or resection) for purulent or feculent peritonitis (Hinchey III-IV).'],
                prevention: ['Colonoscopy 6 weeks after recovery to rule out malignancy.']
              },
              prognosis: {
                mortality: '<1% in uncomplicated cases, high (up to 20%) with perforation',
                factors: 'Hinchey stage determines prognosis and treatment strategy.'
              }
            }
          ]
        }
};
Object.entries(window._abdomen_en || {}).forEach(([k, v]) => {
  window.diseases[k] = Object.assign(window.diseases[k] || {}, v);
});

(function ensureAbdomenEnDiseaseGalleries() {
          const categoryIds = ['gastrointestinal', 'viral_hepatitis', 'urinary_tract', 'intraabdominal'];

          function createInlineGalleryImage(diseaseName, categoryName) {
            const safeDiseaseName = String(diseaseName || 'Disease');
            const safeCategoryName = String(categoryName || 'Abdomen');
            const svg = `<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 1200 630">
      <defs>
        <linearGradient id="bg" x1="0" x2="1" y1="0" y2="1">
          <stop offset="0%" stop-color="#e0f2fe"/>
          <stop offset="100%" stop-color="#bae6fd"/>
        </linearGradient>
      </defs>
      <rect width="1200" height="630" fill="url(#bg)"/>
      <circle cx="1020" cy="150" r="130" fill="#0284c7" opacity="0.14"/>
      <circle cx="180" cy="520" r="180" fill="#0ea5e9" opacity="0.12"/>
      <text x="80" y="150" font-size="62" font-family="Arial, sans-serif" font-weight="700" fill="#0c4a6e">${safeDiseaseName}</text>
      <text x="80" y="230" font-size="36" font-family="Arial, sans-serif" fill="#075985">Category: ${safeCategoryName}</text>
      <text x="80" y="340" font-size="30" font-family="Arial, sans-serif" fill="#082f49">Abdominal infection educational illustration</text>
      <rect x="80" y="390" width="1040" height="8" fill="#0284c7" opacity="0.45"/>
      <text x="80" y="470" font-size="28" font-family="Arial, sans-serif" fill="#0c4a6e">Infectologia</text>
    </svg>`;

            return {
              url: `data:image/svg+xml;utf8,${encodeURIComponent(svg)}`,
              caption: `${safeDiseaseName} - educational illustration`,
              type: 'Illustration'
            };
          }

          const gastrointestinalDefaultMaps = [
            {
              url: 'https://commons.wikimedia.org/wiki/Special:FilePath/Diarrheal_disease_death_rates,_World,_2020.svg',
              caption: 'World map: diarrheal disease death rates (2020)',
              type: 'Epidemiology map'
            },
            {
              url: 'https://commons.wikimedia.org/wiki/Special:FilePath/Diarrheal_disease_prevalence_rates,_World,_2020.svg',
              caption: 'World map: diarrheal disease prevalence (2020)',
              type: 'Epidemiology map'
            }
          ];

          const epidemiologyMapGalleryByDiseaseId = {
            cholera: [
              {
                url: 'https://cdn.who.int/media/images/default-source/cover-images/who-documents/thumbnail_cholera_34.tmb-479v.png?sfvrsn=fae3cc58_2',
                caption: 'WHO cholera situation snapshot (February 21, 2026) - affected countries',
                type: 'WHO epidemiology map'
              },
              {
                url: 'https://upload.wikimedia.org/wikipedia/commons/4/4d/Distribution_of_the_cholera.PNG',
                caption: 'Geographic distribution of cholera (endemic and epidemic areas)',
                type: 'Epidemiology map'
              }
            ],
            salmonellosis: [
              {
                url: 'https://upload.wikimedia.org/wikipedia/commons/8/87/CDC_salmonellosis_map.png',
                caption: 'Salmonellosis epidemiology map (CDC)',
                type: 'Epidemiology map'
              },
              ...gastrointestinalDefaultMaps
            ]
          };

          categoryIds.forEach((categoryId) => {
            const category = window.diseases[categoryId];
            if (!category || !Array.isArray(category.diseases)) return;

            category.diseases.forEach((disease) => {
              if (!disease || (Array.isArray(disease.gallery) && disease.gallery.length > 0)) return;
              if (epidemiologyMapGalleryByDiseaseId[disease.id]) {
                disease.gallery = epidemiologyMapGalleryByDiseaseId[disease.id].map((image) => ({ ...image }));
                return;
              }
              if (categoryId === 'gastrointestinal') {
                disease.gallery = gastrointestinalDefaultMaps.map((image) => ({ ...image }));
                return;
              }
              disease.gallery = [createInlineGalleryImage(disease.name, category.name)];
            });
          });
        })();

      // Ensure urinary_tract didactics are present (EN)
      window.diseases['urinary_tract'] = window.diseases['urinary_tract'] || {};
      Object.assign(window.diseases['urinary_tract'], {
        didactics: {
          overview: 'Distinguish lower (usually without systemic signs) and upper (pyelonephritis, systemic signs) urinary tract infections. Lower UTIs are mostly ambulatory; upper UTIs often require broader work-up and sometimes hospitalization.',
          lower: 'Typical symptoms: dysuria (burning), urinary frequency, urgency, suprapubic discomfort, occasional hematuria. Vital signs usually normal.',
          upper: 'Systemic signs: fever (>38°C), chills, malaise; local: flank/CVA tenderness, nausea/vomiting. Labs: leukocytosis, elevated CRP, pyuria; obtain urine culture and consider blood cultures in febrile patients.',
          diagnostics: ['1) Focused history and vitals', '2) Urine dipstick and microscopy', '3) Urine culture if complicated/recurrent or before treatment when systemic signs present', '4) Blood tests (CBC, creatinine, CRP) and blood cultures if systemic', '5) Imaging (US/CT) if obstruction, persistent symptoms or abscess suspected'],
          red_flags: ['Sepsis signs (hypotension, altered mental status)', 'Rapidly rising creatinine or obstruction', 'Pregnancy with fever', 'Inability to tolerate oral intake (vomiting)', 'Immunosuppression'],
          special_populations: 'Elderly: often atypical (confusion, falls, functional decline) — low threshold for investigation. Children: fever may be the sole sign. Pregnancy: low threshold for treatment and follow-up due to higher risk of pyelonephritis.',
          teaching_tip: 'If urinary symptoms are present without systemic signs → think cystitis. Add fever and flank pain or abnormal vitals → suspect pyelonephritis and escalate evaluation and care.'
        }
      });

export const abdomenEn: DiseaseDatabase = window.diseases;
